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Does Motor Neuron Disease Cause an Impairment in Theory of Mind? 
A Systematic Review 
ABSTRACT 
Title: Does Motor Neuron Disease Cause an Impairment in Theory of Mind? A Systematic 
Review 
 
Objective: Motor neuron disease (MND) disrupts electrical signals between the brain and the 
muscles resulting in physical disability and for some individuals, additional cognitive deficits. 
Research suggests that MND may also be associated with deficits in Theory of Mind (ToM), or 
the ability to interpret other’s emotions. The aim of the systematic review is to provide an up to 
date analysis of the literature investigating ToM in MND. 
 
Methods: The literature search was carried out using Web of Science, PubMed and PsycINFO 
databases on 14th May 2019. Quantitative studies investigating the performance of individuals 
with MND, aged eighteen or over, on ToM tasks in comparison to a control group were included 
in the review. Twenty-five papers were included and were systematically analysed by two 
researchers. 
 
Results: Twenty-one of the twenty-five studies indicated a significant impairment on ToM tasks 
in an MND group compared to a control group with effect sizes ranging from small to large. 
Variable findings are discussed in relation to inconsistently controlled confounding variables 
and heterogeneity within the MND population. 
 
Conclusions: The literature reviewed suggests that ToM deficits are prevalent in the MND 
population. Implications for clinical practice are considered. 
 
9 
 
Keywords: Motor neuron disease, Amyotrophic lateral sclerosis, theory of mind, social 
cognition. 
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INTRODUCTION  
Motor neuron disease (MND) is caused by degeneration of motor neurons in the cortex, the 
brain stem and spinal cord (Desai-Joy, 2000). The disease, also known as amyotrophic lateral 
sclerosis (ALS), disrupts electrical signals between the brain and the muscles resulting in 
weakness, physical disability and speech difficulties. The average age of onset is 56 years and 
prognosis typically ranges between two and five years (Talbot, 2009).  This fatal disease 
results in physical disability and speech difficulties (Talbot, 2009).  
An estimated 50% of people with MND also develop cognitive impairment and 15% develop 
frontotemporal dementia (FTD) (Ringholz et al, 2005). FTD is a progressive condition 
associated with memory difficulties, disinhibition and an impairment in theory of mind (ToM) 
(Bak, 2010). ToM refers to the ability to understand that others have internal experiences 
different to one’s own and to empathise with others (Baron-Cohen, 1991). Cognitive ToM 
denotes the ability to comprehend another person’s perspective and affective ToM refers to the 
ability to understand the emotions of others (Shamay-Tsoory et al., 2004). MND and FTD 
share genetic, clinical and neuropathological features and these two conditions may be best 
conceptualised as related syndromes (Strong et al., 2017). For individuals presenting with 
ALS and comorbid FTD, experts have suggested the term “amyotrophic lateral sclerosis 
frontotemporal spectrum disorder” (ALS-FTSD) (Strong et al., 2017). Due to the shorter life 
expectancy of people with MND, it is currently unknown whether ALS-FTSD may be the 
“natural endpoint” of the condition (Strong et al., 2017).  Due to shared features between these 
two conditions, researchers have begun to investigate whether ToM may also be impaired in 
“pure” MND without dementia.   
ToM is associated with a specialised set of “mirror” neurons which are activated both when an 
individual executes a motor act and when they observe another person performing the same 
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motor act. It has therefore been suggested that the mirror neuron system (MNS) provides a 
neural mechanism for ToM and for empathising (Baird et al., 2010). ToM tasks are associated 
with MNS activity in the amygdala, the inferior frontal gyrus, the right superior temporal sulcus, 
the right inferior parietal lobule, the medial prefrontal cortex, the orbitofrontal cortex, the 
precuneus, the somatosensory cortex and the occipital cortex (Rajmohan & Mohandas, 2007). 
Cognitive and affective ToM tasks recruit intersecting and distinct prefrontal areas (Shamay-
Tsoory et al., 2009). Indeed, lesions to the ventromedial prefrontal areas are associated with 
deficits in cognitive ToM. Conversely, damage to the inferior frontal gyrus is associated with 
impairments in affective ToM (Shamay-Tsoory et al., 2009). Preliminary research in this area 
suggests that people with MND may have deficits in ToM and social cognition in terms of 
recognition of facial expressions, intonation and interpretation of others’ intentions (Girardi et 
al., 2011; Meier et al., 2010; Sedda et al., 2014;). Indeed, poor social awareness can be a cause 
of distress for relatives caring for people with MND (Merrilees et al., 2010).  
A recent meta-analysis of 15 studies reported that MND participants performed significantly 
poorer than controls on tasks of social cognition and emotion recognition with medium effect 
sizes (Bora, 2017). The author also found a significant correlation between executive 
dysfunction and social cognition deficits (Bora, 2017).  The meta-analysis used a small number 
of papers (n=15), did not examine study quality and featured an experiment in which the MND 
sample included participants with comorbid dementia. This is likely to have affected the results. 
Further research has since been published and the current review will, therefore, aim to provide 
an up to date analysis of the literature, ascertain whether “pure” MND causes an impairment in 
ToM abilities and evaluate the methodological quality of the studies in this area. Due to the 
variable tasks used in this area of research it was not appropriate to combine the results in a 
meta-analysis. 
 
12 
METHODS 
The literature search was carried out on 14th May 2019, with databases searched from inception. 
Quantitative studies investigating the performance of individuals with MND, over the age of 18, 
on ToM tasks in comparison to a control group were included (Appendix B, p81). Qualitative 
studies, animal studies, research in languages other than English, case studies and studies with 
children under the age of 18 were excluded. Studies which investigated ToM abilities with 
individuals who had other conditions other than MND or with individuals who had a diagnosis 
of MND with comorbid dementia were excluded. Research examining cognitive or behavioural 
deficits that did not include a measure designed to investigate ToM  were also excluded. Studies 
investigating ToM in different populations, rather than with individuals who had MND, were 
excluded.  
 
Records of titles of 416 papers were retrieved from Web of Science (n=148), PubMed (n=125) 
and PsycINFO (n=143).  Hand searching of reference lists of included papers did not produce 
any relevant papers not already captured from database searches. Following removal of 
duplicates, articles were screened by two researchers against inclusion and exclusion criteria 
(see Prisma flowchart - Appendix C, p82). The 25 papers included were systematically analysed 
by two researchers and evaluated for methodological quality using the Quality Assessment Scale 
for MND Research (QAS-MND) (Appendix D, p83). The QAS-MND was adapted from the 
Case-control studies Assessment Scale (SIGN, 2012) for the current review. At the screening 
for inclusion stage there was 77% agreement between the researchers and at the quality rating 
stage agreement was 85%. Differences of opinion were resolved by discussion, and re-
examination of the study against inclusion and exclusion criteria. Effect sizes were reported 
directly from the studies, where provided. Where effect sizes were not directly reported, these 
were calculated using Cohen’s d (Cohen, 1992) for parametric data or Eta Squared for non-
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parametric data (Fritz et al., 2012; Richardson, 2011). For several studies data was not provided 
to allow calculation of effect size, in which case this is denoted by ESNA. 
RESULTS  
Four studies did not provide the time since symptom onset. For the 21 studies that did provide 
this information, the mean time since symptom onset was 29.7 months (range=18.5-47 months). 
The literature reviewed was of moderate to high quality (mean=10.52; range 7-13) and an 
overview of the results is provided in Table 1. Given research regarding the distinct neural 
substrates of cognitive and affective ToM, studies relating to these areas were reviewed 
separately in the following narrative synthesis (Shamay-Tsoory et al., 2009).  
 
14 
Table 1 Systematic Review Studies Investigating ToM in MND (n=25) 
 
Study Clinical 
Sample 
(n) 
Mean 
months 
symptom 
onset  
Mean 
ALSFRS
-R 
Spinal/ 
Bulbar 
onset  
Sporadic 
/ 
Familial 
Control 
Sample (n) 
ToM Mental 
Health 
Screen 
Background Neuropsychological 
Assessment 
ToM test Results QAS-
MND    
Papps et al. 
2005 
18 Diagnosed 
within 24m 
NA NA S=19 20✓ EFT 
 
 
HADS 
ELQ  
Dementia pts excluded. MND pts sig 
impaired on emotive word memory 
task on cognitive assess.  
No sig group differences on 
EFT once premorbid IQ 
controlled. Total EFT (p=0.08, 
d=0.60, medium ES).  
11 
Gibbons et 
al. 2007 
16 24 NS S=13 
B=3 
S=16 16✓ CST No pts 
showed signs 
of depression 
no measure 
noted 
Dementia pts excluded using 
MMSE MND pts sig impaired on 
Stroop task on cognitive assess. MND 
pts with bulbar symptoms sig 
impaired on block design task & 
picture naming task compared to 
controls & MND pts with spinal 
symptoms only. 
No sig group diff on CST 
(p=0.06, ESNA), however, 
some individual MND pts 
impaired, particularly those 
with bulbar signs. CST 
performance correlated with 
executive task scores. 
8 
Zimmerman 
et al. 2007 
13 NA NA B=13 NA 12✓ EFT  
 
Prosody Test 
MND group 
higher GDS 
scores 
ALS-FTD pts differentiated in 
analysis. MND pts sig impaired on 
MMSE  
MND pts sig impaired on EFT 
(p=0.01; d=1.1, large ES). No 
sig differences on Prosody task 
(p>0.05, d=0.36, small ES). 
GDS not correlated with 
EFT/Prosody task. MMSE 
correlated EFT & Prosody 
scores  
10 
Meier et al. 
2010 
18 34.56 35.78 NA NA 18✓ FPT  
Aprosody 
Test  
HADS scores 
mild & no 
group 
differences 
Dementia pts excluded using 
ACE-R. Cognitive battery. 
MND group sig impaired on 
FPT (p=0.01; d=1.23, large 
effect size) & Aprosody Test 
(p=0.04, d=0.65, medium ES).  
No sig correlation between 
tests & ALS-FRS-R.  
12 
Cavallo et 
al. 2011 
15 24.8 
 
31.33 S=14 
B=1 
NA 21✓ RME  
 
SCT  
HADS 
subclinical 
levels & no 
group 
differences 
Dementia pts excluded. Pts with 
bulbar signs performed sig. poorer on 
cognitive battery. 
No sig group differences RME 
(p>0.05, ESNA), MND group 
sig impaired on SCT (both pts 
with & without bulbar signs)  
(p=0.001, ESNA). No 
correlation between cognitive 
tasks & SCT.  
12 
Girardi et 
al. 2011 
14 38.7 29.7 S=7 
B=7 
S=14 20✓ JPT 
EFT 
RME 
No group 
differences on 
HADS   
Dementia pts excluded. MND pts sig 
impaired verbal memory task on  
cognitive battery. 
MND group sig impaired JPT 
(p<0.001) correlated with 
higher self-rated apathy scores. 
MND sig impaired RME 
(p<0.05) & EFT (p<0.05) on all 
emotions. EFT correlated 
verbal fluency test.  
ESNA. 
12 
Staios et al. 
2013 
35 32.05 36.4 ‘mixed
’ 
NA 30✓ TASIT No group 
differences on 
HADS  
Dementia pts excluded using ACE-R  
MND pts sig impaired on BSAT 
On TASIT MND group 
comparable to controls on 
detection of positive (p>0.05,   
12 
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Study Clinical 
Sample 
(n) 
Mean 
months 
symptom 
onset  
Mean 
ALSFRS
-R 
Spinal/ 
Bulbar 
onset  
Sporadic 
/ 
Familial 
Control 
Sample (n) 
ToM Mental 
Health 
Screen 
Background Neuropsychological 
Assessment 
ToM test Results QAS-
MND    
Staios et al. 
2013 cont. 
         η2=0.01, small ES) & negative 
emotions (p>0.05, η2=0.01, 
small ES) & sincere statements 
(p>0.05, η2=0.03, small effect 
size). Sig impaired compared to 
controls on TASIT sarcastic (p 
<0.05, η2=0.19, large ES) & 
paradoxical sarcastic conditions 
(p<0.05, η2=0.21 large ES) 
after controlling for poorer 
BSAT. 
 
Cerami et al. 
2014 
20  23.9 36.84 S=16 
B=4 
S=20 56✓ EAT 
IAT  
Subclinical  
NPI & 
HDARS & no 
group 
differences 
Dementia pts excluded using MMSE  
Cognitive battery identified  20% pts 
in MND group =ALSci & 10% ALSbi 
No sig group differences in 
intention attribution (p=0.08, 
Cliff’s delta=0.26, small ES) 
MND group sig impaired 
emotion attribution (p =0.03; 
Cliff’s delta=0.33, small ES). 
No correlation between 
executive functions & EAIT.  
10  
Crespi  et al. 
2014 
22 MND 
16 ALS-
FTD 
 
23 NA S=18 
B=4 
S=22 
 
55✓ EFT Clinical NPI-
Q  score pts 
excluded & 
no group 
differences 
Dementia pts excluded  using MMSE. 
Cognitive battery identified 23% 
ALSci; 9% ALSbi; 4%ALSci/bi; ALS 
only 64% 
MND group sig impaired EFT 
anger & disgust (p=0.001; 
r=0.35, medium ES). 
10  
Savage et al. 
2014 
13=MND 
25=FTD 
16=ALS
FTD 
 
NA MND=37
.3 
ALSFTD
=41.2 
S=11 
B=2 
NA 30✓ 
(except for 
years of 
education) 
EFT & 
TASIT  
None Dementia pts in separate group  
screened using ACE-R & cognitive 
battery 
 
No sig differences between 
MND & control group on 
TASIT (p>0.05, d=0.08, below 
threshold for small ES) & EFT 
(p>0.05, d=0.43, small ES). 
ALS-FTD pts sig impaired on 
both. 
10  
Carluer et 
al. 2015 
23 18.78 38.87 S=18 
B=5 
NA 23✓ FBT 
 
21 MND pts 
completed 
NPI-Q, no 
group 
differences 
Dementia pts excluded using MDRS. 
MND pts sig impaired on Hayling 
test, verbal fluency & TMT  on 
cognitive battery 
10 pts=ALSci 
None ALS=bi 
MND group sig impaired on 
FBT (p < 0.001,  η2=0.23, large 
ES).Sig correlations with FBT 
&TMT, verbal fluency & letter 
& number sequencing task.  
8 
Niven et al. 
2015 
40 35.68 38 S=34 
B=6 
S=38 
F=2 
40✓ ECAS social 
cognition 
HADS sig 
higher in 
MND group 
ECAS & cognitive battery identified 
13 MND pts =ALSci 
11 pts had sig impaired social 
cognition score (p<0.05, 
ESNA). Further data not 
available. Validation study for 
ECAS.  
12 
Jelsone-
Swain et al. 
2015 
19 
(13 in 
action) 
47  36.84 NA NA 18✓ (13 
only in  
RME 
Hand action 
task  
No group 
differences &  
MoCA & cognitive battery 
administered 
There was no significant 
difference between the MND & 
control group on RME,  
10 
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Study Clinical 
Sample 
(n) 
Mean 
months 
symptom 
onset  
Mean 
ALSFRS
-R 
Spinal/ 
Bulbar 
onset  
Sporadic 
/ 
Familial 
Control 
Sample (n) 
ToM Mental 
Health 
Screen 
Background Neuropsychological 
Assessment 
ToM test Results QAS-
MND    
Jeslone-
Swain et al. 
2015 cont. 
understan
ding exp) 
    action 
understandi
ng 
experiemen
) 
 Subclinical 
GDS scores 
 although individual MND pts 
were impaired (p> 0.05; 
d=0.54, medium ES). MND 
group sig impaired on action 
understanding (p<0.05; ESNA). 
 
Van der 
Hulst et al. 
2015 
33 31.3 34.7 S=22 
B=11 
NA 26✓ JPT 
IRIQ 
No group 
differences on 
HADS 
Dementia pts excluded using 
ACE-R & MND group sig poorer 
verbal fluency, GNT & FrSBe on  
cognitive battery. 
MND group sig impaired 
empathy IRIQ  (p=0.05, 
ESNA) & impaired on affective 
aspect of JPT  (p=0.01, d=0.74, 
medium ES), but not cognitive 
aspect (p=0.10, d=0.59, 
medium ES). JPT score 
correlated with poor verbal 
fluency, higher apathy on 
FrSBe & poorer GNT.  
12 
Watermeyer 
et al. 2015 
55 31.8 34.05 S=42 
B=13 
NA 49✓ RME 
TASIT 
IRIQ 
CST 
No group 
differences on 
HADS  
Dementia pts excluded  
MND pts sig impaired on DKEFS & 
verbal fluency of cognitive battery  
 
No sig group differences on 
RME (p>0.05, d=0.1 below 
threshold of small ES), TASIT 
(p>0.05, d=0.2, small ES) or 
IRIQ (p>0.05, d=0.04, small 
ES). MND group sig impaired 
on CST Single Inference sub 
test(p= 0.001, d =1.01, large 
ES), Pairs Inference subtest  
(p = 0.002, d = 0.67, medium 
ES) & Written Scenarios 
subtest (p =0.006, d =0.62, 
medium ES). Social cognition 
scores correlated with 
executive function tasks.  
11 
Aho-Ozhan 
et al. 2016 
30  
 
41 27.9 S=21 
B=9 
NA 29 ✓  EFT MND group 
higher BDI 
scores 
Dementia pts excluded using MMSE When difference in BDI scores 
controlled for MND group sig 
impaired on EFT disgust 
(p=0.01, d=0.6, medium ES) & 
fear (p=0.01, d=1.1, large ES). 
11  
Burke et al. 
2016a 
106 NA NA S=78 
B=28 
NA 50✓ RME 
 
NA Dementia pts excluded 
Cognitive battery administered as part 
of population based study 
MND=70 no cognitive deficits; 19 
executive impairment; 19 cognitive & 
executive impairment 
MND sig impaired on RME 
(p< 0.001; η2=0.19, large ES). 
MND group with no cognitive 
deficit performed better than 
MND group with executive 
impairment & MND group 
with cognitive and executive 
impairments had lowest scores 
on RME. 
9 
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Study Clinical 
Sample 
(n) 
Mean 
months 
symptom 
onset  
Mean 
ALSFRS
-R 
Spinal/ 
Bulbar 
onset  
Sporadic 
/ 
Familial 
Control 
Sample (n) 
ToM Mental 
Health 
Screen 
Background Neuropsychological 
Assessment 
ToM test Results QAS-
MND    
Burke et al. 
2016b 
59 Bulbar 
onset 
=10.8m 
since 
diagnosis; 
Spinal=14.
3m since 
diagnosis 
No sig 
differenc
e 
between 
bulbar/sp
inal onset 
pts 
S=39 
B=20 
NA 59✓ JPT 
RME 
MND pts 
higher HADS 
scores. No sig 
difference 
between 
bulbar spinal 
onset HADS 
Dementia pts excluded  
Cognitive battery administered as part 
of population based study. MND pts 
impaired on working memory, verbal 
fluency, backward digit span 
No sig difference between 
MND & control pts on RME 
(p>0.05, ESNA) or JPT 
(p>0.05, ESNA). Bulbar sig 
impaired compared to controls 
on RME.  
 
9 
Trojsi et al. 
2016 
22 18.73 Pts in 
stage 1-2 
KCSS 
S=13 
B=9 
S=22 15✓ ATOM  
EAT 
RME 
No group 
differences on 
BDI  
Dementia pts excluded using  
ACE-R. MND sig poorer memory 
prose test  cognitive battery 
MND group sig impaired EAT 
(p=0.001; η2=0.38, large ES) & 
RME (p=0.004;  η2=0.33, large 
ES). MND group normal range 
on ATOM (p=0.24, η2=0.09, 
medium ES). Bulbar pts more 
impaired than spinal onset. 
EAT & RME correlated with 
education, memory & quality 
of life.  
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Keller et al. 
2017 
65 20.9 39.6 S=50 
B=15 
F=3 
S=62 
33✓ ECAS Social 
cognition 
NA MND pts sig impaired on all aspects 
of ECAS except memory & social 
cognition 
No sig difference between 
groups on ECAS social 
cognition (p=0.309, ESNA) 
11 
Poletti et al. 
2017 
21 33.62 NA S=18 
B=3 
NA 21✓ except 
gender not 
matched 
RME MND group 
STAI & BDI 
higher than 
controls 
Dementia pts excluded using 
MoCA. MND pts sig impaired on 
MoCA, working memory & eye 
tracking ALSbi=4; ALSci=2 
MND sig impaired on RME 
(p=0.03, d=0.8, large ES). No 
correlation between STAI/BDI 
& RME. MoCA & RME 
correlated. 
8 
Radakovic 
et al. 2017 
30 24 39.1 S=25 
B=5 
NA 29✓ EFT 
JPT 
MND group 
sig higher 
GDS score  
Dementia pts excluded. 
MND group impaired verbal fluency 
& PGMT & higher apathy scores on 
cognitive battery 
MND group impaired on JPT 
(p=0.047, η2=0.08, medium 
ES). no sig group differences 
on EFT (p=0.10, d=0.6, 
medium ES). Social cognition 
associated with increased 
apathy. No correlation between 
GDS and social cognition.  
12 
Trojsi et al. 
2017 
21 18.5 41 B=9 
S=12 
S=21 15✓ ATOM 
 EAT 
No group 
differences on 
BDI 
Dementia pts excluded 
Using ACE-R. No sig group 
differences at baseline on cognitive 
battery 
At baseline no sig group 
differences on ATOM/ EAT 
(p>0.05). After 6 months MND 
group sig impaired on EAT 
compared to controls (p<0.05, 
d=0.36, small ES) & MND 
original baseline scores 
(p<0.01, d=0.60, medium ES).  
After 6 months MND group sig 
impaired on ATOM compared 
to controls (p<0.01, d=0.86,  
13 
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✓= matched age sex and education; ACE-R=Addenbrookes Cognitive Examination Revised; ALS-FTD=Amyotrophic Lateral Sclerosis Frontotemporal Dementia; 
ATOM=Advanced ToM Test; BSAT=Brixton Spatial Anticipation test; CATS= Comprehensive Affect Testing System; CBI= Cambridge Behaviour Inventory-Revised; 
CST= Cartoon and Scenarios Test; EAT= The Emotion Attribution Task; EFT=The Eckman Faces Test; ELQ=Emotional Lability Questionnaire; ES=effect size; ESNA= 
ES not available; FBT= False Belief Task; FERT= Facial Emotion Recognition Test; FPT=Faux Pas Test; GNT=Graded Naming Test; IRIQ=The Interpersonal Reactivity 
Index Questionnaire; JPT= The Judgement of Preference Task; KCSS=Kings Clinical Staging System; MDRS= Mattis Dementia Rating Scale; MoCA=Montreal Cognitive 
Assessment; η2= Eta Squared; NPI-Q= Neuropsychiatric Inventory Questionnaire; Pts=participants; RME= The Reading the Mind in the Eyes Test; SCT=The Story 
Completion Task; STAI=State Trait Anxiety Inventory; TASIT=The Awareness of Social Inference Test; TMT=Trail Making Test;ToM-15= Theory of Mind 15 Items. 
 
 
 
Study Clinical 
Sample 
(n) 
Mean 
months 
symptom 
onset  
Mean 
ALSFRS
-R 
Spinal/ 
Bulbar 
onset  
Sporadic 
/ 
Familial 
Control 
Sample (n) 
ToM Mental 
Health 
Screen 
Background Neuropsychological 
Assessment 
ToM test Results QAS-
MND    
Trojsi et al. 
2017 cont. 
         large ES) and original MND 
baseline (p<0.01, d=0.81, large 
ES). Bulbar onset impaired 
EAT & ATOM, spinal onset 
only impaired EAT. 
 
Andrews et 
al 2017 
33 35.7 36.4 B=11 
L=22 
NA 22✓ CATS No clinical 
severity on 
HADS  
Individuals with dementia diagnosis 
excluded & those with cognitive 
impairment on  ACE-R. No sig group 
difference on ACE-R. 
MND group sig impaired on BSAT 
MND group impaired on 
complex facial expression  (p = 
0.001, r =0.47, medium ES),  
and prosody emotion 
recognition (p=0.002, r =0.41, 
medium ES). Simple facial 
affect recognition (p=0.67, 
r=0.06, below threshold for 
small effect) and semantic 
affect comprehension 
unimpaired (p=0.13, r=0.21, 
small ES). Sig correlation 
between BSAT & CATS. 
10 
Martins et 
al. 2019 
21 36 NA S=18 
B=3 
S=21 25 ✓  FERT MND 
significantly 
higher HADS 
scores 
Dementia pts excluded using MMSE/ 
No sig group difference on MMSE. 
MND group only completed verbal 
fluency test & CBI-R to classify type 
MND. 
MND group sig poorer 
recognition of sadness on 
FERT only (p=0.004, r=0.43, 
medium ES). No correlation 
between MMSE & FERT. 
7 
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Cognitive ToM 
Seven studies examined cognitive ToM. Three of the seven studies exploring this did not report 
significant differences between the MND and control groups. MND participants performed 
comparably to controls on the Intention Attribution Task (IAT) (Happé, 1994), involving 
suggesting a plausible ending to social stories (Cerami et al., 2014) and on a version of the 
Judgement of Preference Task (JPT), which entails deciphering which of four pictures in a box 
a cartoon face in the centre is “thinking of” (Van der Hulst et al., 2015).  Trosji et al. (2016) 
administered the Advanced Theory of Mind Test (ATOM) (Happé, 1994), involving 
understanding the behaviour of story characters. This study which was rated the highest quality 
(QAS-MND=13) reported that the control group performed comparably to the MND group 
(mean months since symptom onset=18.73 months) on the ATOM. 
 
On the contrary several studies reported that MND participants were significantly impaired on 
a false belief task (TOM-15) (Carluer et al., 2015),  a story completion task (SCT) (Ciaramidaro 
et al., 2007; Cavallo et al., 2011) and an assessment involving deciphering intention based on 
hand movements (Jelsone-Swain et al., 2015). Trosji et al. (2017) also conducted a follow up 
study, rated as the highest quality (QAS-MND=13). The authors reported that in accordance 
with their previous findings MND participants (mean months since symptom onset=18.5) and 
controls were tested on the ATOM and cognitive tests at baseline and the two groups performed 
comparably. When retested six months later, however, bulbar and spinal onset MND 
participants showed a significant decline in ATOM scores compared to controls and a proportion 
of the MND group had developed ALS with cognitive impairment (ALSci) (n=2) and ALS with 
behavioural impairment (ALSbi) (n=2) (Trojsi et al., 2017). This may indicate that cognitive 
ToM deficits become more prevalent as the disease progresses. 
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With regards to neurological findings, data from positron emission tomography (PET) during 
the ToM-15 task revealed that the MND group’s poorer performance correlated with 
hypometabolic activity in the supplementary motor area and the dorsomedial and dorsolateral 
prefrontal cortices (Carluer et al., 2015). Furthermore, functional magnetic resonance imaging 
(fMRI) scanning during the hand action intention attribution task revealed that poorer 
performance within the MND group was associated with reduced activity in the prefrontal cortex 
and middle temporal gyrus (Jelsone-Swain et al., 2015). Finally, Trojsi et al., (2016) reported 
reduced FMRI activity in frontotemporal areas at baseline and at six months in the MND group 
compared to controls during the ATOM. 
 
QAS-MND ratings of studies which found a significant impairment in cognitive ToM 
(mean=10.75; range=8-13) were comparable to quality ratings of the experiments which did not 
report significant group differences in cognitive ToM (mean =11.66; range=10-13). Inconsistent 
findings in this area do not appear to be accounted for by differences in overall study quality. 
Studies that did not find significant group differences on cognitive theory of mind tasks typically 
reported small to medium effect sizes (Cerami et al., 2014; Trosji et al., 2016; Van der Hulst et 
al., 2015), whilst the studies finding significant group differences reported large effect sizes 
(Carluer et al., 2015; Trosji et al., 2017), or the effect size data were not available (Cavallo et 
al., 2011; Jelsone-Swain et al., 2015). As such it is possible that non-significant results may be 
attributable to the studies being underpowered, however, larger studies would be required to 
investigate this further. 
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Affective ToM 
 
Twenty-four studies investigated affective ToM. Seventeen studies reported that MND groups 
performed significantly poorer on tasks of Affective ToM than control groups and seven studies 
did not replicate this finding. Several studies have administered the Reading the Mind in the 
Eyes Test (RME) (Baron-Cohen et al., 2001) and reported a significant impairment in MND 
groups (Burke et al., 2016a; Girardi et al., 2011; Trojsi et al., 2016; Poletti et al., 2017). Four 
studies did not replicate this finding (Burke et al., 2016b; Cavallo et al., 2011; Jelsone-Swain et 
al., 2015; Watermeyer et al., 2015).   
 
Some studies reported that MND participants performed comparably to controls on The Eckman 
Faces Test (EFT) (Young et al., 2002), which entails deciphering emotion portrayed by facial 
expressions (Papps et al., 2005; Radakovic et al., 2017; Savage et al., 2014). On the contrary, 
other studies have reported that individuals with MND perform significantly poorer on EFT 
compared to controls (Aho-Ozhan et al., 2016; Crespi et al., 2014; Girardi et al., 2011; Martins 
et al, 2019; Zimmerman et al., 2007). Andrews et al. (2017) reported that the MND group 
performed comparably to controls on the basic version of the EFT, but were impaired when 
asked to identify corresponding prosody or match multiple expressions.  
 
The Awareness of Social Inference Test (TASIT), involves identifying the emotion of actors in 
social scenes (McDonald et al., 2003). Whilst some studies have suggested individuals with 
MND are impaired on TASIT compared to neurotypicals (Staios et al., 2013), other studies have 
not found significant group differences (Savage et al., 2014; Watermeyer et al., 2015). 
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Meier et al. (2010) found that MND participants were significantly impaired on a faux pas test 
of affective ToM during which examinees must detect the emotional states of characters and an 
aprosody task involving discerning emotions from phonetic information. Similar experiments 
reported that people with MND performed significantly poorer on affective prosody tasks 
(Andrews et al., 2017; Zimmerman et al., 2007). 
 
The affective ToM version of the Judgement of Preference Task (JPT) consists of asking 
respondents to identify which of four pictures a cartoon face “likes the best” (Girardi et al., 
2011). Three studies found MND participants performed significantly poorer on the JPT 
compared to control subjects (Girardi et al. , 2011; Radakovic et al. 2017; Van der Hulst et al., 
2015) and one study did not (Burke et al., 2016b). Niven et al. (2015) found MND participants 
were significantly impaired on a JPT subtest of the Edinburgh Cognitive and Behavioural ALS 
Screen (ECAS) compared to control subjects, although other research has failed to replicate this 
finding (Keller et al., 2017).  
 
Van der Hulst et al. (2015) reported that an MND group rated themselves as significantly less 
empathetic than controls on The Interpersonal Reactivity Index Questionnaire (IRIQ). 
Watermeyer et al. (2015) did not identify any group differences on the IRIQ, however, ten of 
the fifty-five MND participants fell below the cut off score for empathetic concern or 
perspective taking. 
 
Watermeyer et al. (2015) reported that the MND group performed significantly poorer than 
controls on the Happé Cartoon and Scenarios Test (CST) which involves identifying the story 
character’s emotions (Happé, Brownell & Winner, 1999). In a similar experiment involving 
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identifying story characters’ emotions, the MND group performed significantly poorer than 
controls (Cerami et al., 2014). Gibbons et al. (2007) did not find significant group differences 
on the CST.  
 
Trojsi et al. (2016, 2017) also conducted high quality research (QAS-MND=13) using the 
Emotion Attribution Task (EAT), during which the examinee is asked to identify the emotion 
of a story character (Happé, 1994). The MND group had a mean of 18.73 months since symptom 
onset and were significantly impaired on EAT compared to neurotypicals (Troksi et al. 2016). 
Whilst further research by Trojsi., (2017) with individuals at a similar stage of disease (mean 
months since symptom onset=18.5) found no significant group differences on the EAT at 
baselines, after six months the MND group had developed an impairment on EAT (Trojsi et al., 
2017).   
 
With regards to neurological findings, voxel-based morphometry during an emotion attribution 
experiment demonstrated that poorer performance correlated with reduced grey-matter density 
in the anterior cingulate cortex and right inferior frontal gyrus within the MND group (Cerami 
et al., 2014). Crespi et al. (2014) found that poor performance on the EFT in an MND group 
correlated with abnormalities in white matter of the right inferior longitudinal fasciculus and 
inferior fronto-occipital fasciculus, identified using diffusion tensor imaging. Research using 
fMRI reported that MND participants showed increased activity in the right inferior frontal 
gyrus and decreased activity in the hippocampus bilaterally when processing images of sad faces 
on the EFT (Aho-Ozhan et al., 2016). FMRI analysis during EAT task revealed reduced 
connectivity in prefrontal areas in the MND group within the posterior cingulate, precuneus and 
medial prefrontal cortices (Trosji et al., 2017). The authors reported positive correlations 
between atypical activity in the prefrontal cortex, affective ToM and disease duration. 
 24 
 
QAS-MND ratings of seventeen studies which found a significant impairment in affective ToM 
in the MND group (QAS-MND mean=10.82; range=8-13) were comparable to quality ratings 
of the seven experiments which did not report significant group differences (QAS-MND 
mean=10.14; range=8-12). There are, therefore, inconsistent findings in this area that do not 
appear to be accounted for by differences in overall study quality.   
Studies which found a significant affective ToM deficit in the MND group compared to controls 
reported small (Cerami et al., 2014 & Trosji et al., 2017), medium and large effect sizes (Aho-
Ozhan et al., 2016;  Andrews et al. 2017; Crespi et al., 2014; Burke et al., 2016a; Martins et al, 
2019; Meier et al., 2010; Poletti et al., 2017; Radakovic et al., 2017; Staios et al., 2013; Trojsi 
et al., 2017; Van der Hulst et al., 2015; Watermeyer et al. (2015); Zimmerman et al., 2007). For 
two of the studies reporting significant results, effect size data were not available (Girardi et al., 
2011 & Niven et al., 2015). The studies which did not find significant group differences reported 
small (Savage et al., 2014) and medium effect sizes (Jelsone- Swain et al., 2015 & Papps et al., 
2005). However these data were not available for the majority of studies which did not report 
significant group differences (Burke et al., 2016b; Cavallo et al., 2011; Gibbons et al., 2007; 
Keller et al., 2017).  
DISCUSSION  
The majority of the studies reviewed reported that MND groups performed significantly poorer 
on ToM tasks compared to control groups with small to large effect sizes. This finding is 
accordance with a previous meta-analysis which reported that MND groups demonstrated a 
significant deficit in ToM compared to controls, with medium effect sizes (d=0.65) (Bora, 
2017). Further to Bora’s (2017) meta-analysis of fifteen studies, the current paper which 
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reviewed twenty-five papers suggests that individuals with “pure” MND, without dementia, may 
develop affective and cognitive ToM deficits. Additionally, the current review suggests that 
both spinal and bulbar onset variant MND are associated with cognitive and affective ToM 
deficits (Cavallo et al., 2011; Trojsi et al., 2017) and ToM difficulties appear to become more 
prevalent as the disease progresses (Trojsi et al., 2017; Van der Hulst et al., 2015). The research 
suggests that individuals with ALSbi and ALSci may be more vulnerable to developing ToM 
impairments (Carluer et al., 2015; Cerami et al., 2014). Some studies reported a correlation 
between executive function and ToM deficits (Gibbons et al., 2007; Watermeyer et al., 2015). 
The current study highlights that ToM impairments can, however, occur in the absence of wider 
executive dysfunction (Cavallo et al., 2011; Cerami et al., 2014) and appear to reflect focal 
neurological atrophy (Aho-Ozhan, 2016; Trosji et al., 2017). Finally, ToM deficits may be more 
pronounced in bulbar onset MND than in limb onset MND (Burke et al., 2016; Trosji et al., 
2016).  
 
The majority of studies reported a significant impairment in ToM in the MND group compared 
to control participants. A limited number of studies, however, did not replicate these results. 
Some of the research which did not report significant group differences, reported that individual 
MND participants in the sample were impaired (Gibbons et al., 2007; Jelsone-Swain et al., 
2015). Inconsistent findings in this area therefore may be a reflection of the heterogeneity of the 
MND population. Furthermore, studies reporting significant impairments in the MND group in 
terms of cognitive and affective ToM appeared to report larger effect sizes, compared to many 
of the studies reporting non significant results. Thus some studies may have been underpowered 
to detect relatively small differences between groups. However, this finding also highlights the 
heterogeneity in effect sizes observed across studies. 
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Variable findings were not attributable to significant differences in overall study quality, 
however, they may be related to inconsistency in controlling for confounding variables. Most 
experiments controlled for anxiety and depression levels, with the exception of Savage et al. 
(2014), Burke et al. (2016a) and Keller et al. (2017). Only ten of the experiments took 
precautions to minimise the effects of fatigue (Cavallo et al., 2011; Cerami et al., 2014; Girardi 
et al., 2011; Meier et al., 2010; Niven et al., 2015; Papps et al., 2005; Trojsi et al., 2016; Trosji 
et al., 2017; Van der Hulst et al., 2015; Watermeyer et al., 2015). Three studies excluded 
participants taking medication which may affect cognitive functioning (Papps et al., 2005; Trojsi 
et al., 2016; Trojsi et al., 2017).  Only two of the studies conducted a power analysis (Burke et 
al., 2016a; Trojsi et al., 2017) and non-significant effects may also be attributed to inadequate 
sample sizes. Differences between hereditary and sporadic MND were not analysed by any of 
the studies and may explain some variance in ToM difficulties. Studies reporting an absence of 
ToM deficits in the MND population may feature patients in less advanced stages of the disease, 
or a lower proportion of bulbar onset patients who appear to present with a more pronounced 
ToM impairment (Trojsi et al., 2016). This is in accordance with the results of a recent review 
which suggested that bulbar onset MND may be associated with a poorer prognosis (Shellikeri 
et al., 2017). Finally, the studies used a diverse range of tasks which may be of variable 
sensitivity to detecting ToM impairments.   
The current review is limited by the small sample sizes used in most of the studies. This analysis 
can only provide a preliminary discussion of the relationship between ToM and different aspects 
of MND, such as bulbar, spinal, familial or sporadic MND subtypes, as these variables have not 
been well researched. Although the review focused on “pure” MND, it is possible that the 
experiments featured MND participants in the early stages of undetected dementia who may not 
have met the threshold for diagnosis. This review reflects deficits in the early stages of the 
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disease. Further research is required to investigate how ToM is affected in the later stages of the 
condition. It is not explicitly stated by any of the authors of the studies included whether MND 
patients recruited for their studies have also taken part in other research.  Trojsi et al. (2016, 
2017), however, both recruited from the ALS Center of the First Division of Neurology of the 
Universita degli Studi della Campania. Consequently there may be some degree of overlap 
between individuals with MND who took part in these studies. Due to low incidence of MND 
and rapid progression of the disease, there is likely to be few MND participants able to 
participate in research and the same people may be taking part in the multiple studies. As such 
results should be interpreted with caution, as this may reduce the generalizability of findings. 
In terms of methodological recommendations, the quality of research would be improved by 
consistently controlling for confounding variables. More specifically, when conducting research 
in this area, all participants’ medication use should be recorded as this may affect performance 
on tests. Results may be more accurate when testing is scheduled prior to the time individuals 
are due to take any sedating medications. Additionally, it is important to minimise the effects of 
tiredness on cognitive performance by undertaking testing in the morning. The Epworth 
Sleepiness Scale is most commonly used to compare fatigue levels between MND and control 
groups (Johns, 1991). Researchers should assess whether MND participants are medically fit to 
partake in the research, particularly noting any respiratory problems. Larger sample sizes would 
allow for subgroup analysis. Future research is required to explore the relationship between 
ToM and disease stage. Due to lengthy assessment processes, time since symptom onset, or 
King’s Clinical Staging System, may provide a more accurate indication of disease stage than 
time since diagnosis. Studies conducted over several time points would help determine whether 
ToM deficits become more prevalent as the disease progresses.  
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Research suggests that carers of MND sufferers are distressed by changes in their relatives’ 
social conduct and ability to empathise (Lillo et al, 2012). With regards to clinical practice, it 
may be helpful to provide psychoeducation to individuals with MND and their families about 
the possibility of experiencing difficulties with ToM during the course of their condition. This 
may encourage more explicit discussion of emotions, improve interpersonal relationships and 
increase compassion for individuals living with MND. 
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MRP Plain English Summary 
Investigating the Perception of Emotion Portrayed Through Body 
Movements in Motor Neuron Disease. 
Background 
Motor Neuron Disease (MND) is a degenerative condition, which disrupts signals sent from the 
brain to the muscles resulting in physical disability. Some individuals can also experience 
difficulties with tasks involving thinking, reasoning and perception. In the advanced stages of 
the disease, this fatal condition causes difficulties breathing and the heart can stop working. 
Recent research suggests that people with MND can have difficulties understanding the facial 
expressions and emotions of other people. 
 
Aims  
To date research has not yet explored whether people with MND have difficulties interpreting 
emotions portrayed by body movements. The current study aims to investigate whether MND 
causes an impairment in the ability to understand other people’s emotions through body 
language.  
 
Methods  
Fifteen people who had a diagnosis of MND were recruited for the study. Fifteen individuals 
who did not have any neurological or mental health conditions were also recruited. These 
participants are referred to as the control group. Both groups were asked to complete a test of 
basic motor skills, a test of reasoning skills and a questionnaire to identify psychological 
distress. Both groups completed well established tests widely used in clinical practice which 
involved identifying a person’s emotion through life like social interactions (TASIT) or through 
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basic facial expression (ECAS). Both groups also completed a new test called E-Motion, which 
asks people to interpret emotions portrayed by body movements without any cues from facial 
expressions. It was predicted that the MND group would perform significantly poorer than the 
control group on the E-Motion test.  
 
Results  
The MND group’s scores were compared to the control group’s scores on tests using statistical 
analysis. The findings suggested that the MND group performed significantly poorer than 
control participants on the new E-Motion test. However, no firm conclusions can be drawn 
regarding whether MND is associated with difficulties understanding emotions through body 
movements. This is because E-Motion is a new assessment tool that requires further testing to 
ensure it is valid for this use.  
 
The results indicate that the MND group scored lower than the controls on the TASIT, 
although these differences were not statistically significant. Individuals with MND scored 
significantly lower than the controls on the ECAS social cognition test. The results of the well-
established TASIT and ECAS social cognition tests are consistent with previous research 
findings and indicate that some individuals with a diagnosis of MND may experience 
difficulties understanding other people’s emotions. The current study is limited by the small 
number of participants and the use of the E-Motion test which has not yet been validated. 
Further research is required to investigate the validity of E-Motion. In order to explore 
whether the results of this study are representative of the wider MND population, future 
research with higher numbers of participants is required. 
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Investigating the Perception of Emotion Portrayed Through Body 
Movements in Motor Neuron Disease. 
ABSTRACT  
Objectives  
Motor Neuron Disease (MND) disrupts signals between the brain and the muscles causing 
physical disability and speech difficulties. Recent studies suggest that Theory of Mind (ToM), 
or the ability to interpret facial expressions and empathise with others’ emotions, can be 
impaired by MND. Research has, however, not yet investigated whether MND causes deficits 
in understanding emotion portrayed by body movements. The current study used a novel 
computerised assessment tool, E-Motion, which was developed with the aim of assessing the 
ability to interpret emotions through body movements. The primary hypothesis was that 
individuals with MND would be impaired compared to control participants on the E-Motion 
test.  
 
Methods  
Fifteen individuals with MND and fifteen neurotypical participants were recruited via an MND 
patient register and opportunity sampling. Participants completed cognitive and psychological 
assessments and ToM assessments: a subtest of the Awareness of Social Inference Test 
(TASIT), the Edinburgh Cognitive and Behavioural ALS Screen social cognition test (ECAS) 
and the E-Motion assessment.  
 
Results  
A Mann-Whitney U Test indicated that the MND group performed significantly poorer on the 
E-Motion test with a large effect size (p<0.01, Eta squared=0.35, 90% CI [0.14, 0.59]) and on 
the ECAS social cognition subtest, with a medium effect size (p=0.02, Eta squared=0.19, 90% 
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CI [0.02, 0.41]) compared to controls. An independent t-test indicated that the MND group 
attained lower scores on the TASIT subtest compared to controls with a medium effect size, 
although group differences were not significant (p=0.17, d=0.51, CI[-0.21,1.24]).  
 
Conclusions 
Although the E-Motion results suggest possible MND-associated deficits in understanding body 
language, interpreting data from this task is significantly limited because the E-Motion task has 
not yet been formally validated.  In particular, the E-Motion task requires formal development 
and validation studies. These studies would be required to quantify its performance across 
internal, external and content validity metrics to allow firmer conclusions to made.  Findings 
from the E-Motion task should not be over-interpreted, and should be regarded as provisional 
and exploratory. Further research on tool development and replicating findings will be needed 
to advance the evidence-base in this area.  The results of the validated ECAS social cognition 
test suggest that some individuals with MND may develop difficulties in understanding the 
emotions of others. This finding is in accordance with previous research in this area. Further 
research in larger sample sizes and subtypes of MND are required to ascertain whether ToM 
deficits are prevalent in the wider MND population. 
 
Keywords: Motor neuron disease, amyotrophic lateral sclerosis, theory of mind, social 
cognition, body movement. 
 
 
 
 
 41 
Investigating the Perception of Emotion Portrayed Through Body 
Movements in Motor Neuron Disease. 
 
BACKGROUND 
Motor Neuron Disease (MND) refers to a group of conditions caused by a progressive 
degeneration of the upper motor neurons in the cortex and the lower motor neurons located in 
the brain stem and spinal cord (Talbot, 2009). The most common variant, Amyotrophic Lateral 
Sclerosis (ALS) affects upper and lower motor neurons resulting in muscle stiffness and 
weakness. The Progressive Muscular Atrophy (PMA) variant causes a deterioration of the lower 
motor neurons and is associated with muscle atrophy, weakness and weight loss. The Primary 
Lateral Sclerosis (PLS) variant, affects upper motor neurons, and is associated with muscle 
spasticity, particularly in the limbs and a longer life expectancy than other types of MND. The 
average age of onset for MND is 56 years, with a life expectancy of between two and five years 
(Talbot, 2009). MND disrupts signals between the brain and the muscles resulting in physical 
disabilities and speech difficulties (Talbot, 2009).  
Approximately 50% of MND patients also develop a cognitive impairment. Furthermore, an 
estimated 15% of individuals develop comorbid frontotemporal dementia (FTD), a progressive 
condition associated with memory difficulties, disinhibited behaviour and Theory of Mind 
(ToM) deficits (Bak, 2010). ToM refers to the ability to empathise and to understand that others 
have internal experiences different to one’s own (Bora, 2017). Interestingly, a review of the 
literature concluded that individuals with a diagnosis of “pure” MND without FTD may also 
have deficits in ToM in terms of recognition of facial expressions and interpretation of others’ 
intentions (Bora, 2017). Research has suggested that social communication and understanding 
can also be impaired in MND, which may be a cause of distress for patients and caregivers (Lillo 
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et al., 2012). Furthermore, the literature suggests that ToM deficits in MND can occur in the 
absence of wider executive dysfunction and appear to reflect focal neurological atrophy 
(Cavallo et al., 2011).  
 
Mirror neurons are a set of specialised neurons activated when an individual performs a 
particular motor act or observes another person performing the same motor act (Di Pellegrino 
et al., 1992).  It has been suggested that a network of these specialised neurons, the Mirror 
Neuron System (MNS), enables humans to understand other people’s mental states and to 
empathise. Neuroimaging studies have implicated neurons within the areas of the hippocampus, 
motor cortex, pars opercularis of the inferior frontal gyrus and the rostral posterior parietal 
cortex in the MNS (Dapretto et al., 2006; Mukamel et al., 2010; Vigneswaran et al., 2013). It 
has been proposed that damage to the MNS may underlie deficits in ToM associated with 
various disorders such as autism (Pickett & London, 2005). 
 
Biological motion perception refers to the human ability to identify and interpret the movement 
of living organisms and is thought to have evolved for the purposes of survival and social 
interaction (Atkinson et al., 2007). Experiments have shown that point light displays conveying 
biological motion provide adequate information for participants to ascertain the action and 
emotional state of the figure (Brownlow et al., 1997; Johansson, 1973). Lulé et al. (2007) 
reported that compared to controls, MND patients showed reduced activation in the right middle 
temporal lobe, an area associated with the understanding of biological motion. Furthermore, 
individuals with MND appear to be impaired in terms of visualising actions (Fiori et al., 2013) 
and understanding action words (Bak & Hodges, 2004). The ability to deduce emotion from 
physical movement has, however, not yet been explored in MND.  
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Aims and Hypothesis 
The current study uses E-Motion, a novel test which aims to assess a specific aspect of ToM; 
the ability to understand emotions through body gestures. The experiment aims to ascertain 
whether individuals with MND demonstrate an impairment on E-Motion compared to the 
neurotypical population. Based on the literature proposing possible ToM and biological motion 
deficits in MND, the primary hypothesis predicted that the MND group’s mean score on the E-
Motion task would be significantly poorer than the control group’s mean score on the E-Motion 
task.   
 
METHODS 
Participants 
With regards to sample size, a related study reported that individuals with MND were impaired 
at interpreting facial expressions compared to control groups with an effect size of 0.8 (Oh et 
al., 2016).  An a-priori power analysis conducted using G*Power software indicated a sample 
of 15 MND participants and 15 control participants powered at .80 with an alpha of .05 would 
enable an effect size of .93 to be detected in the current experiment (Faul et al., 2007). This is a 
larger effect size than reported by Oh et al. (2016), but E-Motion involves the interpretation of 
more subtle body movements and may therefore, be more sensitive to detecting ToM 
impairments. Through discussion with other local researchers working in the field of MND, it 
was determined that recruiting 15 participants would also be attainable in the time available. An 
invitation to take part in the study was sent to individuals on the Scottish MND register and their 
spouses. Additional control participants were also recruited via opportunity sampling.  
 
To meet the inclusion criteria, participants in the MND group had a diagnosis of MND, were 
fluent in English and were 18 years or older. To be eligible to take part in this study, participants 
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within the MND group were required to demonstrate capacity to consent as agreed by the 
treating team at the MND Service. All cases were discussed with the patient’s MND nurse. An 
estimated thirty five percent of individuals with MND develop a cognitive impairment, below 
the threshold indicative of dementia, whilst fifty percent do not develop any cognitive 
difficulties (Ringholz et al., 2005). Approximately fifteen percent of individuals with a diagnosis 
of MND develop comorbid frontotemporal, a syndrome known as ALS-FTD (Ringholz et al., 
2005). As cognitive impairment is a common symptom of MND, individuals with MND who 
demonstrated comorbid cognitive impairment were eligible for inclusion in the study. 
Participants with ALS-FTD were not eligible to take part, as this is considered a distinct 
syndrome. Participants with MND with a diagnosis of other dementia subtypes or comorbid 
neurological conditions were not eligible to take part. Exclusion criteria for the MND group also 
included a history of substance misuse or diagnosis with another psychological disorder. 
Neurotypical controls were fluent in English, 18 years or older, with no diagnosis of 
neurological or psychological conditions or substance misuse.  
 
Sixteen control participants were recruited, however, one control participant was excluded from 
the analysis, having demonstrated significant cognitive impairment on testing. All participants 
were provided with a debriefing sheet with details of support organisations and were advised to 
discuss any concerns regarding mental and physical health with their GP (appendix J, p120). Of 
those control participants included in the analysis, seven were still working and eight were 
retired. Two participants in the control group self-reported that they had previously experienced 
depression, from which they had recovered. Six participants in the control group reported 
current physical conditions which were well managed at the time of the study and were not 
considered likely to affect cognitive functioning. Consequently these individuals were retained 
in the sample. 
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Fifteen individuals who had a diagnosis of MND were recruited. Five participants had a 
diagnosis of Primary Lateral Sclerosis and ten had a diagnosis of ALS. Within the MND group, 
only one individual was working and fourteen had retired. The time since symptom onset ranged 
from six months to seventeen years (mean= 6.5 years) and the time since diagnosis ranged from 
six months to twelve years (mean= 2.4 years). The majority of the sample presented with limb 
onset MND (n=14) and only one participant reported bulbar onset symptoms. Fourteen 
participants presented with sporadic MND and one participant had a first-degree relative with 
the condition. One participant in the MND group had a previous physical health condition and 
one MND participant described experiencing depressive symptoms for which they had received 
treatment. Four MND participants reported having additional physical health conditions which 
were not neurological in nature. As these conditions were not deemed likely to affect cognitive 
performance and were well managed at the time of the experiment, these participants were 
retained in the study.  
 
Procedure  
This study was granted ethical approval by the Nottingham Ethics Research Committee 
(Appendix E, p87; Appendix F, p107). Data was stored in a secure password protected 
spreadsheet, in line with data protection regulations. Testing was carried out in a quiet clinic 
space and within patients’ homes. Precautions were taken to mitigate risks to the researcher and 
participants during this process (Appendix G, p111). Prior to taking part all control participants 
were informed that individual feedback was not provided regarding the results of testing as the 
battery is not a complete neuropsychological assessment and does not include a clinical 
interview required to interpret results. Prior to testing all MND participants consented to the 
results of the ECAS and HADS-M being shared with their treating MND team and consented to 
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any clinical concerns being shared with the treating MND team. All MND participants were 
informed that MND can result in cognitive difficulties for some individuals. All MND 
participants were informed that they could access their ECAS and HADS-M results through 
arranging an additional neuropsychological testing session and a clinical interview with a 
Neuropsychologist by contacting their MND nurse. Prior to taking part participants were 
provided with an information sheet (Appendix H, p115) before being asked for their consent to 
participate (appendix I, p118). Following the study participants were provided with a debriefing 
form (appendix J, p120). The testing session took approximately one hour thirty minutes and 
participants were offered breaks to minimise the effects of fatigue and pain, issues frequently 
experienced by people with MND. Research costs were funded by the University of Glasgow 
(Appendix K, p122). 
 
Background Measures 
In order to obtain an estimated premorbid IQ, the Test of Premorbid Functioning (TOPF; 
Wechsler, 2011) was administered to all participants, with the exception of two MND 
participants who were unable to complete this test due to dysarthria. 
 
Cognitive Screening 
Performance on ToM tests may be impeded by cognitive deficits and executive dysfunction. As 
such, the sample also completed the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) 
(Niven et al., 2015). The ECAS has been specifically designed to account for dysarthria or 
agraphia associated with MND. Participants write or verbalise answers depending on preserved 
motor functions and subtests account for motor speed difficulties in score calculations. The 
ECAS provides a total score, an ALS specific score, indicating cognitive impairment related to 
MND neuropathology and an ALS non-specific score, indicating cognitive impairments 
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unrelated to ALS neuropathology. An additional informant-rated ECAS questionnaire, which 
provides information about behavioural and cognitive symptoms, was not completed for six 
MND participants as an informant was unavailable.  
 
Psychological Assessment 
Affective disturbance may also influence participants’ performance on tests of cognitive 
abilities. Consequently, all control subjects completed the Hospital Anxiety and Depression 
Scale (HADS; Zigmond & Snaith, 1983). All MND participants completed a version of the 
HADS specifically adapted for this population (HADS-M; Gibbons et al., 2011). For example, 
items likely to reflect motor difficulties rather than mood for people with MND, such as “I feel 
as if I am slowed down”, are removed from the HADS-M.   
 
Baseline Motor Skills 
All participants completed the praxis subtest of the Kaplan Baycrest Neurocognitive Assessment 
(Leach et al., 2000). Participants were asked to replicate a range of transitive and intransitive 
pantomime actions as a measure of the ability to interpret basic movements in the absence of 
emotional cues.  
 
Test of Social Awareness 
All participants completed a subtest of the Awareness of Social Inference Test (TASIT; 
McDonald et al., 2003). This subtest requires participants to identify happiness, sadness, anger, 
anxiety and neutral emotion from videotaped social scenes.  
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Test of the Perception of Emotional Body Movements 
Both groups completed the E-Motion test, a novel assessment tool created for the study with the 
aim of assessing the ability to interpret emotions through body language. The E-Motion stimuli 
were developed from data in a motion capture library (Ma, Paterson & Pollick, 2006).  In-depth 
descriptions of the E-Motion instrument can be found in a previous publication Ma, Paterson & 
Pollick (2006). The motion capture library stores data obtained from paid actors portraying 
emotions through body movements whilst wearing body movement sensors. Professor Pollick, 
Professor of Psychology and Hyuga Tanimoto, Computer Programmer, accessed the data in the 
library to develop the animations of figures. A combination of software including Character 
Studio (plug-ins for 3D Studio Max, AutoDesk Inc.) and Matlab (The Mathworks) was used to 
develop the stimuli. The figures did not feature facial expressions to ensure that the task is reliant 
on recognising emotions through the body movements alone. E-Motion can be administered on 
a computer using a Microsoft Powerpoint presentation with embedded videos presenting stimuli 
of different emotions. E-Motion is exclusively a visual assessment and there are no verbal cues. 
The assessment consists of 16 consecutive stimuli showing a figure in every possible 
combination of the four emotions (happy, angry, sad, afraid) and four actions (walking, 
knocking, lifting, throwing). These 16 stimuli are repeated in three sequential phases with 
progressively less information. During phase one, participants are presented with the 16 stimuli 
as full figure animations (Figure 1); in phase two, the 16 stimuli are presented as lines (Figure 
2) and in phase three, the 16 stimuli are presented as a point light display (Figure 3). We 
predicted that this design may make it increasingly difficult to interpret as less cues will be 
available to participants as the phases progress.  In total, each participant was presented 48 video 
stimuli (16 from phase one, 16 from phase two, 16 from phase three). 
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The stimuli within each phase were randomised before the start of the study by the lead 
researcher using an online randomiser number generator. The same order of 48 stimuli was 
presented consistently to all participants. Each emotional stimuli video lasted thirty seconds and 
participants were given 10 seconds following the end of the video to answer from a multiple 
choice format of four emotions (happy, sad, afraid, or angry) placed on a card in front of them. 
Participants were also asked to rate their confidence in each answer from 0-100%.  
 
The 48 confidence ratings were added together and the total divided by 48 to provide a measure 
of average confidence for each participant. An actual accuracy score was also calculated as a % 
of items correct out of 48 for each participant. The actual accuracy score was deducted from the 
perceived confidence score to produce an “insight” score (either a positive or negative value 
depending on whether the individual overestimated or underestimated their actual accuracy). 
This score was designed to provide a measure of the individual’s insight into their ability on E-
Motion. Further details of the development process of E-Motion are available in appendix L 
(p124). 
 
Figure 1: Phase 1 Full Figure                                       Figure 2: Phase 2 Line Figure  
Anger Throwing Condition                                         Sad Walking Condition  
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Figure 3: Phase 3 Point Light Dot  
Afraid Knock Condition 
 
 
 
 
 
 
  
Data Analysis 
Normality testing for each variable was carried out using the Shapiro-Wilk test in combination 
with inspection of box plots and histograms in order to select the appropriate parametric or non-
parametric statistical test. Firstly demographic differences between the two groups were 
explored. Differences in age, education and IQ of the two groups were investigated using an 
independent samples t-test. A Mann-Whitney U test was used to explore differences in HADS 
scores between the two groups and a Chi-Square Test of Independence was used to analyse 
gender differences between the two groups. 
 
Between group differences on neuropsychological tests were analysed using independent t-tests 
for normally distributed variables and Mann-Whitney U tests for non-normally distributed 
variables. Due to the directional hypothesis regarding E-Motion, one-tailed independent t-tests 
and one-tailed Mann-Whitney U tests were used to investigate group differences on this test. 
Two-tailed independent t-tests and Mann-Whitney U tests were used to explore group 
differences regarding performance on all other measures. In accordance with research 
recommendations Cohen’s d effect sizes were calculated for independent t-test results (Field, 
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2013) and eta-squared effect sizes were calculated for Mann-Whitney U results (Fritz et al., 
2012) using an online calculator (Lenhard & Lenhard, 2016). For Cohen’s d effect sizes 95% 
confidence intervals were calculated (Lenhard & Lenhard,  2016). However, in accordance with 
recent guidelines (Kelley, 2007; Smithson, 2003), 90% confidence intervals were calculated for 
Eta squared effect sizes, using an online calculator (Uanhoro, 2017). 
 
Exploratory subgroup analyses were then carried out examining within group gender differences 
and subtypes of MND. Due to the small sample sizes involved in these analyses, the Mann-
Whitney U test was used. Associations between the years since symptom onset and performance 
on the TASIT, E-Motion and the ECAS social cognition, were explored using two-tailed non 
parametric spearman’s rho correlations, due to abnormally distributed data. The relationships 
between E-Motion and other tests of social cognition were also analysed using two-tailed 
spearman’s rho correlations, due to abnormally distributed data.  95% Confidence intervals for 
Spearman’s rho correlations were calculated using an online calculator for Spearman’s rho  
(Evans, 2019).  Finally the internal consistency of E-Motion was explored using Cronbach’s 
alpha.  
 
RESULTS  
Sample Characteristics 
There were no significant differences between groups with regards to age, years of education, 
TOPF, HADS-A or HADS-D scores (Table 1.1 & 1.2). Two participants in the MND group 
were unable to complete the TOPF due to severe dysarthria. Years of education may, therefore, 
provide a more accurate indication of prior intellectual functioning for the sample. There were 
no significant differences in gender distribution between the MND and control group (Table 
1.3).  
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Table 1.1 Sample Characteristics 
Independent Samples t-test 
Variable MND (n=15) Control  
(n=15) 
t (df) 
 
p 
 
d 95 % CI for d 
mean SD mean SD Lower Upper  
Age (yrs) 64.70 7.05 61.89 6.34 1.15 
(28) 
0.26 0.42 
small 
-0.30 1.14 
Education 
(yrs) 
13.23 2.91 14.53 2.75 -
1.26(28) 
0.22 0.46 
small 
-0.27 1.18 
TOPF 
(IQ) 
99.69 12.82 107.13 11.92 -
1.59(26) 
0.93 0.50 
Medium  
-0.13 1.33 
Levene’s test >0.05=equality of variances assumed for age, years of education & TOPF 
* Cohen’s d  effect sizes= 0.20 small; 0.50 medium and 0.80 large (Cohen, 1998). 
*Abbreviations: CI=confidence intervals; d=Cohen’s d; df=degrees of freedom; p=significance 
value; SD=standard deviation; TOPF test of Premorbid functioning 
 
Table 1.2 Sample Characteristics 
Mann-Whitney U test  
Variable MND 
Group 
Control 
Group  
U  p-
value 
Eta 
Squared  
90% CI for 
Eta 
Squared Mdn IQR Mdn IQR 
HADS-A 5.00 5.00 6.00 9.00 70.0 0.08 0.01 
small 
0.00 0.14 
HADS-D 2.00 3.00 2.00 5.00 109.0 0.88 0.001 
no effect 
 
0.00 
 
0.07 
* Eta squared effect sizes: 0.01 small, 0.06 medium, 0.14 large (Adams & Conway, 2014).Eta 
Squared values & CI are given to the nearest two decimal places and values 0.00 are >0.  
*Abbreviations: CI=confidence intervals; HADS-A=Hospital Anxiety and Depression Scale 
Anxiety subscale; HADS-D=Hospital Anxiety and Depression Scale Depression subscale; 
IQR=Interquartile range; Mdn=Median; p=significance value. 
 
Table 1.3 Sample Characteristics 
Chi-Square Test of Independence 
Variable MND 
(n=15) 
Control 
(n=15) 
χ2 (df) p Cramer’s 
V 
M F M F 0.27 
small Gender 11 4 7 8 2.22(1) 0.13 
*Cramers V effect sizes: 0.10 small; 0.30 medium; 0.5 large. (Kim, 2017). 
*Abbreviations: Df=degrees of freedom; p=significance value;  χ2 = Chi Squared Value. 
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Between Group Differences on Neuropsychological Tests   
 
The analysis revealed that MND participants were significantly impaired compared to controls 
with regards to the total ECAS score and all ECAS subtests with medium to large effect sizes 
(Table 2). The results of the ECAS questionnaire suggested that the MND group reported 
significantly more behavioural difficulties compared to the neurotypical group. This result 
should, however, be interpreted with caution due to missing data for six MND participants, for 
whom informants were unavailable. The MND group also performed significantly poorer than 
the control group on the ECAS social cognition subtest with a large effect sizes (Table 2). The 
MND group scored on average lower than the control group on the TASIT with a medium effect 
size, although group differences did not reach significance. The analysis showed that individuals 
with MND also scored significantly lower than control participants on the praxis test with a 
large effect size (Table 2). It should be noted that confidence intervals shown in table 2 indicate 
that effect size are broad and indicate that the true effect size for significant results may range 
from small to large in magnitude.  
  
In comparison to controls, MND participants attained significantly lower scores on the full 
figure, line, lifting and knocking and throwing conditions of the E-Motion test with large effect 
sizes (Table 3). The MND group’s mean overall E-Motion total score was also significantly 
lower than the control group’s mean score. Confidence intervals suggest that the true difference 
between groups was within the large range (Table 3). The MND group also significantly 
overestimated their accuracy on the E-Motion test compared to controls, as indicated by the E-
Motion insight score (with a large effect size). However, as shown in table 3 the results indicate 
that there are significant group differences on E-Motion total and some subscales, however, the 
confidence intervals indicate that we cannot be certain whether these effects are small or large 
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in magnitude. These results support the primary hypothesis that the MND group would perform 
significantly poorer than the control group on the E-Motion test. Control participant’s mean 
scores were higher than the MND participant’s mean scores in terms of discerning the emotion 
from point light, walking, sad, happy, afraid and angry stimuli with small to medium effect sizes 
(table 3). However, differences on these subscores did not reach statistical significance (p>0.05) 
(Table 3).   
* Cohen’s d  effect sizes= 0.20 small; 0.50 medium and 0.80 large (Cohen, 1998). 
* Eta squared effect sizes: 0.01 small, 0.06 medium, 0.14 large (Adams & Conway, 2014). Eta 
Squared values & CI are given to the nearest two decimal places and values 0.00 are >0. 
*Abbreviations CI=confidence intervals; d=Cohen’s d; df=degrees of freedom; SD=standard 
deviation; ECAS=The Edinburgh Cognitive and Behavioural ALS Screen; TASIT=The 
Awareness of Social Inference Test. 
 
 
 
Table 2 
Between Group Analysis ECAS, TASIT & Praxis Tests 
2-tailed 
Independent 
t-test 
MND Control t (df) p d 95% CI for d 
mean SD mean SD lower upper 
TASIT  Total 22.73 3.52 24.20 2.01 -1.40* 
(22.25) 
0.17 0.51 
medium 
-0.21 1.24 
ECAS Total 103.60 20.42 118.73 7.07 -2.71* 
(17.31) 
0.02 0.99 
large 
0.23 1.75 
ECAS ALS 
non-specific 
27.53 4.90 30.13 2.64 -1.81 
(28.00) 
0.81 0.66 
medium 
-0.07 1.40 
ECAS ALS 
specific 
76.07 17.02 88.60 7.09 -2.63* 
(18.72) 
0.02 0.96 
large 
0.20 1.67 
ECAS exec 
function 
34.13 8.82 41.27 4.48 -2.79* 
(20.77) 
0.01 1.02 
large 
0.26 1.78 
*Levene’s Test <0.05 =Equal variances not assumed 
Levene’s Test >0.05=Equal variances assumed (for ECAS ALS non-specific subscale) 
2-tailed Mann 
Whitney U 
test 
 
MND Control U P Eta 
squared 
90% CI for 
Eta Squared 
Mdn IQR Mdn IQR Lower Upper 
ECAS social 
cognition 
12.00 3.50 12.00 0 75.00 0.02 0.19 
large 
0.02 0.41 
ECAS 
Questionnaire 
1.00 
 
4.00 0.00 
 
0 
 
27.00 
 
<0.01 
 
0.38 
large 
0.14 
 
0.59 
Praxis 40.00 17.00 40.00 0 67.50 0.02 0.23 
large 
0.08 0.47 
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* Cohen’s d  effect sizes= 0.20 small; 0.50 medium and 0.80 large (Cohen, 1998). 
* Eta squared effect sizes: 0.01 small, 0.06 medium, 0.14 large (Adams & Conway, 2014). Eta 
Squared values & CI are given to the nearest two decimal places and values 0.00 are >0.  
*Abbreviations: CI=confidence intervals; d=Cohen’s d; df=degrees of freedom; Mdn=median; 
IQR=interquartile range; SD=standard deviation. 
 
Table 3 Between Group Analysis E-Motion Test 
1-tailed 
Independent 
t-test 
MND Control t (df) p d 95% CI for d 
mean SD mean SD lower upper 
E-Motion 
Lines 
9.00 1.51 10.40 1.40 -2.63 
(28.00) 
0.01 0.96 
large 
0.21 1.72 
E-Motion 
Point Light 
9.80 1.78 10.93 1.53 -1.87 
(28.00) 
0.36 0.68 
medium 
-0.04 1.44 
E-Motion 
Walk 
10.13 1.06 10.20 1.37 -0.15 
(28.00) 
0.44 0.05 
small 
-0.66 0.77 
E-Motion Lift 3.80 1.32 5.60 1.30 -3.77 
(28.00) 
<0.01 1.37 
large 
0.59 2.17 
E-Motion 
throw 
7.93 1.44 8.93 1.39 -1.94 
(28.00) 
0.03 0.70 
large 
-0.03 1.44 
E-Motion sad 7.60 2.06 8.60 1.50 -1.52 
(28.00) 
0.07 0.55 
medium 
-0.17 1.28 
E-Motion 
happy 
7.80 1.57 8.67 1.59 -1.50 
(28.00) 
0.07 0.55 
medium 
-0.18 1.28 
E-Motion 
afraid 
7.60 2.06 7.67 1.59 -0.10 
(28.00) 
0.46 0.38 
small 
-0.68 0.75 
E-Motion 
Insight 
20.05 14.55 7.93 9.93 2.66 
(28.00) 
<0.01 1.01 
large 
0.25 1.77 
Levene’s test >0.05=equality of variances assumed for all t-test data above  
Table 3 continued. 
1 tailed 
Mann-
Whitney U 
MND Control U P Eta 
squared 
90% CI for Eta 
Squared 
Mdn IQR Mdn IQR lower Upper 
E-Motion 
Total 
29.00 3.00 34.00 3.00 34.0 <0.01 0.35 
Large  
0.14 0.59 
E-Motion 
Figure 
10.00 2.00 11.00 3.00 51.5 <0.01 0.22 
Large  
0.03 0.45 
E-Motion 
angry 
8.00 2.00 9.00 3.00 85.5 0.13 0.04 
Small 
0.00 0.22 
E-Motion 
knock 
7.00 2.00 8.00 2.00 65 0.02 0.13 
Large 
0.00 0.35 
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Exploratory Subgroup Analysis 
 
Mann-Whitney U tests were used to explore gender differences within groups and Eta squared 
effect sizes were calculated (η2) In the control group there were no significant differences 
regarding E-Motion scores of males (n=7, Mdn=33) and females (n=8, Mdn=34) (U=21.5, 
p=0.45,  η2=0.03, 90% CI [0.00, 0.45]). On the TASIT, however, male control participants (n=7, 
Mdn=23) performed significantly poorer than female controls with a large effect size (n=8, 
Mdn=25) (U=6, p=0.01, η2=0.45, 90% CI [0.12, 0.74]). Male control participants (Mdn=12) and 
female control participants (Mdn=12) performed comparably on the ECAS social cognition test 
(U=28, p=1.00, η2=0.00, 90% CI not available due to no variance).There were no significant 
differences in terms of the performance of male MND participants (n=11, Mdn=29) and female 
MND participants (n=4, Mdn=28) on the E-Motion test (U=21.5, p=0.947, η2=0.00, 90% CI not 
available due to low variance), the TASIT test (M Mdn= 22, F Mdn=25; U=9.5, p=0.10, 
η2=0.04, 90% CI [0.00, 0.30]) or the ECAS social cognition test (M Mdn=12, F Mdn=12, 
U=19.5, p=0.70, η2=0.01, 90% CI [0.00, 0.19]). 
 
Within the MND group, a Spearman's correlation analysis indicated that there were no 
significant associations between years since symptom onset or diagnosis and severity of 
difficulties on the TASIT, E-Motion or any sub conditions of E-Motion or the ECAS (p=>0.05; 
rs=-0.12 to 0.4). Fourteen participants had limb onset and one participant reported bulbar onset 
MND. Fourteen MND participants presented with sporadic variant and one reported a family 
history of this condition. With the limited sample size, it was not possible to undertake any 
meaningful sub analysis of these variables. The scores of the individual with bulbar onset MND 
were comparable to other MND participants within this group and did not represent outliers on 
any assessments. The individual with familial MND performed within the lower range of the 
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MND group on E-Motion and attained the lowest score on praxis, the TASIT, ECAS total, ALS 
specific and ALS non-specific aspects of the ECAS. Mann-Whitney U tests did not reveal any 
significant differences between individuals with PLS (n=5) and MND (n=10) with regards to 
performance on the ECAS social cognition  (PLS Mdn=12, MND Mdn=12, U=19.5, p=0.42, 
η2=0.03, 90% CI [0.00, 0.29]), TASIT (PLS Mdn=25, MND Mdn=23, U=22.5, p=0.77, η2=0.01, 
90% CI [0.00, 0.19]), or E-Motion tests (PLS Mdn=30, MND Mdn=28.5, U=11, p=0.08, 
η2=0.01, 90% CI [0.00, 0.22]).  
 
Within the MND group, seven of the participants’ ECAS total scores and ALS-specific scores 
fell below the threshold indicative of cognitive impairment relating to MND. Two of these 
participants also showed signs of ALS non-specific cognitive deficits. The group of MND 
participants who had a comorbid cognitive impairment (MNDci) (n=7, mean time since 
symptom onset= 5.87 years) was comparable to the group of “pure” MND participants who did 
not have any cognitive impairments (MNDp) (n=8, mean time since symptom onset= 7 years) 
in terms of disease stage.  
 
Mann-Whitney U tests were used to explore differences between individuals with “pure” MND 
referring to individuals who did not display a cognitive deficit (MNDp), individuals with MND 
and a comorbid cognitive impairment (MNDci) and control participants, as data were not 
normally distributed. Individuals with MNDci performed poorest across all three social 
cognition tests. Regarding the E-Motion test, individuals with MNDci attained lower scores 
compared to the MNDp group with a medium effect size, however, the difference did not reach 
significance (U=16.5; p=0.18; η2=0.07, 90% CI [0.00, 0.37]). When analysed separately, both 
the MNDp group and MNDci group performed significantly poorer on E-Motion compared to 
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controls with large effect sizes (MNDp: U=24, p=0.02, η2=0.24, 90% CI [0.03, 0.62];  MNDci: 
U=10, p<0.01, η2=0.41, 90% CI [0.15, 0.71]).  
 
 
 
 
 
 
 
 
 
*Abbreviations: Mdn=median; MNDci: MND with cognitive impairment; MNDp= “pure” 
MND without cognitive impairment; IQR=interquartile range. 
 
The MNDci group performed significantly poorer than the MNDp group on the TASIT (U=3.5, 
p=0.004, η2=0.54, 90% CI [0.17, 0.72]) with a large effect size. The MNDci group also 
performed significantly poorer than the MNDp group on the ECAS social cognition test with a 
large effect size, however, confidence intervals indicate that the true magnitude of the effect 
may have been within the small to large range (U=13.5, p=0.05, η2=0.27, 90% CI [0.01,0.70]). 
MNDci participants attained significantly lower scores than the control group on the TASIT 
(U=13.5, p<0.01, η2=0.35, 90% CI [0.05,0.65]) with a large effect size, although confidence 
intervals indicate that the true effect may have been within the small to large range.  MNDci 
participants performed significantly poorer than the controls on the ECAS social cognition test 
with a large effect size (U=22.5, p<0.01, η2=0.45, 90% CI [0.15, 0.90]). Individuals in the MND 
group who did not demonstrate a cognitive impairment performed comparably to the control 
group on the TASIT (U=43.5, p=0.28, η2=0.05, 90% CI [0.00, 0.38]) and ECAS social cognition 
test (U=52.5, p=0.17, η2=0.01, 90% CI [0.00, 0.17]). 
 
 
 
Table 4 Social Cognition Tests 
Assessment 
 
Control 
(n=15) 
MNDp (n=8) MNDci 
(n=7) 
Mdn IQR Mdn IQR Mdn IQR 
E-Motion total 34.00 3.00 29.00 3.00 28.00 5.00 
TASIT 25.00 2.00 25.50 4.00 20.00 5.00 
ECAS social 
cognition 
12.00 0.00 12.00 0.00 9.00 7.00 
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Exploring the Relationships Between E-Motion and Other Variables 
The relationships between the three social cognition tests; E-Motion, TASIT and ECAS social 
cognition, in addition to the relationship between ToM abilities, cognitive impairment and 
executive function were explored. As these variables were not normally distributed and the 
sample sizes between groups were small, Spearman’s correlation was used for this analysis.  
 
Within the MND group, analysis revealed positive correlations between ECAS social cognition 
and ECAS executive function scores (rs=0.69, p<0.01, 95% CI [0.27, 0.89]) and between ECAS 
social cognition and  ECAS total (rs= 0.88, p<0.01, 95%CI [0.66, 0.96]) with large effect sizes. 
The TASIT positively correlated with ECAS executive function scores (rs= 0.70, p<0.01, 95% 
CI [0.29, 0.89]) and the ECAS total (rs=0.57, p=0.03, 95%CI [0.07, 0.84]) with results 
indicating large effect sizes. ECAS social cognition was also positively associated with the 
TASIT  with a large  effect size (rs= 0.701, p<0.01, 95% CI [0.29, 0.89]). Within the MND 
group, the E-Motion total was not correlated with years of education or the ECAS total score or 
executive function scores. Within the MND group there were no significant correlations 
between E-Motion test and the TASIT and effect sizes were below the threshold for a small 
effect (rs=0.02, p=0.93, 95% CI [-0.5, 0.53]) or ECAS social cognition test (rs=-0.03, p=0, 95% 
CI [-0.53, 0.49]). Within the control group there were no significant correlations regarding the 
three social cognition tests and any other variables examined. Within the control group there 
were no significant correlations between the E-Motion test and the TASIT (rs=0.36, p=00.18, 
95% CI [-0.19, 0.74]) or ECAS social cognition test (rs=0.00, p=0, 95% CI not available due to 
no variance). The correlation between the TASIT and E-Motion test within the control group 
met the threshold for a small effect size. Spearman’s Rho correlational analysis of the combined 
MND and control groups (n=30) identified a positive association between E-Motion and 
executive function (rs= 0.42, p=0.02, 95% CI [0.07, 0.68]), praxis (rs=0.399, p=0.03, 95% CI 
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[0.04, 0.66] and ECAS total (rs= 0.48, p=0.01, 95% CI [0.15, 0.72]) with effect sizes within the 
medium range. Within the whole sample there was no significant relationships between E-
Motion and the TASIT and effect sizes were within the small range (rs=0.25, p=0.13, 95% CI 
[-0.12, 0.56]) or ECAS social cognition test (rs=0.29, p=0.11, 95% CI [-0.08, 0.59]). The 
sample’s TASIT scores positively correlated with ECAS executive function scores and indicated 
a medium association (rs= 0.38, p=0.04, 95% CI [0.24, 0.76]). The results indicated a large 
positive association between ECAS social cognition and ECAS executive function (rs=0.55, 
p<0.01, 95% CI [0.2, 0.74]) and a medium positive correlation between ECAS social cognition 
and praxis (rs= 0.39, p=0.04, 95% CI [0.03, 0.66]). The sample’s ECAS social cognition scores 
positively correlated with their performance on the TASIT  with a medium effect size (rs= 0.43, 
p=0.02, 95% CI [0.08,0.68]).  Interestingly, individual participants within the MND group 
attained high scores on the ECAS social cognition, TASIT, ECAS executive function or ECAS 
total, but demonstrated an impairment on E-Motion.  
 
Internal Consistency Analysis of the E-Motion Test 
In order to assess internal consistency of the E-Motion test, a post hoc Cronbach’s alpha test 
was used to analyse the whole sample’s responses (n=30) to the E-Motion stimuli (Cronbach, 
1951). Guidelines vary, however, Hinton et al. (2004) suggest that a Cronbach’s alpha of 
below 0.5 indicates poor reliability, an alpha of 0.5 to 0.7 is indicative of moderate reliability 
and an alpha value of above 0.7 suggests high reliability. The total E-Motion scale consists of 
48 items. Each stimuli number, phase, emotion and movement type is provided in Appendix L, 
table L.2  (page 122). All respondents (n=30) achieved 100% accuracy on items 29, 33, 41 and 
45 and as such these items were excluded by the Cronbach’s alpha analysis. The full E-Motion 
test (excluding items 29, 33, 41 and 45) had low internal consistency (α=0.38, 95% CI [0.02, 
0.66]). The Cronbach’s alpha analysis indicated that removal of item numbers 3, 6, 7, 9, 11, 
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13, 17, 18, 22, 28, 30, 34, 39, 46 and 48 would improve Cronbach’s alpha for the total E-
Motion scale (α=0.67, 95% CI [0.47, 0.82]).  
 
The internal consistency of each emotion subscale; happiness, sadness, anger and fear were 
also explored. The happy subscale  consists of 12 items. Following the removal of items 29 
and 33 from the analysis due to having no variance, the reliability of the happy subscale was 
calculated as poor (α=0.23, 95% CI [-0.26, 0.58]). Further removal of items 6 and 27 from the 
happy subscale improves the internal consistency somewhat, however, the alpha remains 
within the poor range (α=0.44, 95% CI [0.08, 0.70]). The anger subscale consisted of 12 items, 
however only 11 items were analysed due to item 45 being discounted, due to having no 
variance in the sample. The removal of item number seven would improve the original 
moderate internal consistency of the anger subscale from an alpha of  0.55 (95% CI [0.27, 
0.76]) to 0.58 (95% CI [0.31, 0.77]). The internal consistency of the afraid subscale, consisting 
of 12 items (α=0.51, CI [0.2, 0.73]) was within the moderate range. The analysis indicated that 
the internal consistency of the afraid subscale would be improved by the removal of  items 17, 
31 and 43 (α=0.56, CI [0.28, 0.76]). The sad subscale consisted of 12 items, however, item 41 
was not included in the analysis due to there being no variance. The remaining 11 items of the 
sad subscale indicated poor internal consistency (α =0.46, 95% CI [0.12, 0.71]). The 
Cronbach’s alpha analysis suggested that removal of items 3, 39 and 48 would improve the 
internal consistency of this subscale to within the moderate range (α=0.61, 95%CI [0.36, 
0.79]). 
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DISCUSSION  
ToM Impairments in MND 
The results of the current study support the primary hypothesis that the MND group would 
demonstrate a significant impairment on E-Motion compared to controls. The findings regarding 
E-Motion indicated a large effect size. However, it is important to note that the test has not yet 
been formally validated and as such firm conclusions regarding whether MND is associated 
with difficulties understanding emotional body language cannot be made. The MND group, 
however, did perform poorer across all three social cognition tests compared to the control group 
and differences between groups on the validated ECAS social cognition subtest were significant. 
These findings are in accordance with previous research which has highlighted ToM deficits in 
the MND population (Bora, 2017). The results of the current study suggest that some individuals 
with this condition, may develop ToM deficits. Indeed carers of MND sufferers can experience 
distress related to changes in their loved one’s social conduct (Lillo et al., 2012). With regards 
to clinical practice, it may be helpful to provide psychoeducation to patients and their families 
about the possibility of experiencing difficulties with ToM during the course of their condition. 
This may increase understanding and improve interpersonal relationships.  
 
Exploratory Subgroup Analysis  
The ECAS total scores indicated that seven MND participants (46%) presented with cognitive 
impairment. This proportion is consistent with previous estimates that 50% of individuals with 
MND develop a cognitive impairment (Ringholz et al., 2005). The MND group as a whole and 
the MNDp and MNDci groups performed significantly poorer than the control participants on 
the E-Motion test with large effect sizes. Confidence intervals indicated that the true effect size 
was indeed within the large range for differences between the MNDci and control group on E-
Motion. However, confidence intervals indicate that true effect sizes may have ranged between 
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small to large regarding group differences between the MNDp group and control group on E-
Motion.  
 
Only the MNDci group demonstrated a significant impairment on TASIT compared to controls 
with a large effect size. This result is in accordance with findings of a previous study, which 
reported that individuals with MND and comorbid cognitive deficits showed a significant 
impairment on the TASIT compared to controls (Savage et al., 2014). Individuals with “pure” 
MND, however, scored within the normal range on this test (Savage et al., 2014). Findings are, 
however, mixed and a another study reported that individuals with “pure” MND were impaired 
compared to controls on the TASIT (Staios et al., 2013).  Inconsistent findings regarding social 
cognition deficits and individuals with MNDci and MNDp may be attributable to considerable 
heterogeneity of this population in terms of clinical symptomology and time since symptom 
onset. Indeed, research suggests that ToM difficulties appear to become more prevalent as the 
disease progresses (Trojsi et al., 2017). 
 
In comparison to the control group, the whole MND group and MNDci sub-group demonstrated 
impairment on the ECAS social cognition test, a version of the Judgement of Preference Task  
with large effect sizes (JPT). Interestingly, individuals with MNDp were not significantly 
impaired on this test although results indicated a small effect size. These findings suggest that 
this subtest may only be sensitive to relatively pronounced ToM difficulties, likely to be present 
in the context of broader cognitive impairment. Indeed, Niven et al. (2015) reported that 30% 
(n=12) of participants in their MND group demonstrated an impairment on the ECAS social 
cognition test. Eleven of the individuals impaired on the ECAS social cognition test had 
comorbid cognitive impairments and only one had an isolated ToM impairment.  
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Exploratory use of E-Motion Tool 
This experiment provides the first exploratory use of E-Motion as a proposed ToM test. 
Performance on the ECAS social cognition test was positively associated with performance on 
the TASIT with medium to large effect sizes. The E-Motion test, was not significantly 
associated with the other social cognition tests, although the results showed a weak association 
between E-Motion and TASIT within the small range. It is therefore, possible that E-Motion 
does measure ToM constructs related to those measured by the TASIT and that within a larger 
sample size, further significant correlations between E-Motion and other ToM tests would be 
detected.  
 
Another possible explanation for the dearth of correlations between E-Motion and other tests is 
that the three social cognition tests may be measuring different aspects of ToM. Indeed MND 
participants attained lower scores than controls on the TASIT, although group differences did 
not reach significance. The MND group was significantly impaired on ECAS social cognition 
test with a medium effect size and on E-Motion with a large effect size. It is therefore also 
possible that all three tests detect different aspects of ToM with variable sensitivity. 
 
The variation in sensitivity of the three social cognition tests may be understood in the context 
of the functional organisation of the MNS. Imaging studies have demonstrated that the premotor 
area of the MNS, involved in understanding motor acts, is somatotopically arranged (Fabbri-
Destro & Rizzolatti, 2008). Accordingly, when an individual observes another person 
performing movements with different parts of the body, distinct cortical areas of the premotor 
MNS are activated. Similarly, there is emerging evidence that neurological mirroring occurs in 
the processing of auditory information. This auditory mirroring is associated with distinct and 
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overlapping areas of the MNS such as the insula, auditory cortex, superior temporal gyrus, 
angular gyrus, Wernicke’s area and Broca’s area (Stephens et al., 2010).  
 
It is possible that in situations where there are more cues available (i.e. auditory and visual, 
facial and body movements), individuals who have sustained damage to an area of the MNS 
during the course of MND may be able to compensate using other intact areas of their MNS. 
During the TASIT, the examinee is asked to ascertain the emotion of an actor through auditory 
and visual cues in naturalistic social situations. The ECAS social cognition subtest examines 
ToM through direction of eye gaze of a cartoon face and as such provides fewer cues in 
comparison to the TASIT. The E-Motion test requires examinees to deduce the emotion of a 
figure from subtle body movements alone. Tasks such as the TASIT feature auditory, visual, 
facial and body movement cues. It is possible that individuals who have an MND and a 
comorbid impairment in ToM related to a focal MNS region may have been more able to mask 
the deficit by using alternative cues on the TASIT.  
 
Analysis revealed that all three ToM tests were positively associated with executive function 
and general cognitive abilities with medium to large effect sizes. Interestingly, when examining 
the performance of MNDci and MNDp participants separately, only participants with MNDci 
exhibited deficits on the TASIT and ECAS social cognition subtest with large effect sizes. In 
contrast, both individuals with MNDci and MNDp demonstrated significantly poorer 
performance on the E-Motion test compared to controls with large effect sizes. Furthermore, 
results demonstrated that individual MND participants were impaired on E-Motion despite 
normal TASIT, ECAS total, social cognition and executive function scores. An impairment on 
the E-Motion test does not appear to reflect lower levels of education, global cognitive 
impairment or broader executive dysfunction. Results of the E-Motion test must be interpreted 
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with caution, as the assessment has not yet been validated. However the current study suggests 
that E-Motion appears to be detecting an impairment distinct from global cognitive deficits. This 
is in accordance with previous findings that the ToM deficits associated with MND appear to 
be “over and above” wider executive dysfunction or cognitive impairment (Cavallo et al., 2011; 
p2).  
 
With regards to the internal consistency data, results indicate sub-optimal and highly variable 
reliability for the overall scale and subscales. In the format used in the study the E-Motion total 
scale as a whole (α=0.38), the happy subscale (α=0.23) and sad subscale (α=0.46) demonstrated 
poor internal consistency (Hinton et al., 2004). However, analysis of anger subscale as used in 
the study (minus item 45 which was excluded due to having no variance) indicated moderate 
internal consistency (α=0.55) (Hinton et al., 2004). The afraid (α=0.51) subscale as used in the 
study, prior to removal of any items also appears to demonstrate moderate internal consistency 
(Hinton et al., 2004). It is important to note that confidence intervals provided for alpha values 
relating to the angry and afraid subscales indicated that the true range of internal consistency 
for these scales may range from low to high. The broad confidence intervals are likely a result 
of low sample sizes and a low number of items involved in the Cronbach’s analyses (Bujang et 
al., 2018).  It is possible that the discriminatory power of E-Motion, to differentiate between 
MND and control groups is based on the anger and afraid subscales, rather than the test as a 
whole. The wide variation in subscale reliability suggests that there is a need for comprehensive 
optimization to ensure all scales yield high internal consistency, before further use. 
 
Limitations and Suggestions for Future Research 
The results of the validated ECAS social cognition test suggest that some individuals with MND 
develop ToM deficits. The exploration of any differences in social cognition deficits between 
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bulbar and limb onset MND and familial and sporadic presentations is beyond the scope of the 
current study due to the small sample size. It was not possible to explore the relationship 
between behavioural impairments and social cognition due to missing informant questionnaire 
data. There is a dearth of research regarding these aspects of MND in relation to ToM and further 
investigation is required.  
 
The current study provides preliminary data for the E-Motion assessment tool. However it is 
important to note that the validity and reliability of the test has not been established.  The MND 
group were significantly impaired on E-Motion compared to the control group which may 
indicate that some individuals with MND may have a difficulty with a particular aspect of ToM, 
specifically understanding emotional body language. However, E-Motion did not significantly 
correlate with other ToM tests in the current study. This suggests that either E-Motion is not 
measuring ToM, or as discussed it may be that it is sensitive to  a different aspect of ToM than 
is captured by the TASIT and ECAS social cognition tests. Further research in a large 
neurotypical population comparing E-Motion to a broader range of ToM tests and informant 
measures of ToM would be required to investigate convergent validity. 
 
It is a significant limitation of the study that the internal consistency analysis was run post hoc, 
rather than in the initial development phase of the tool. The Cronbach’s alpha results are also 
limited by the use of a mixed sample of individuals with MND and control participants.  
Research suggests that a sample size of 30 is required for Cronbach’s analysis and as such it 
was not appropriate to analyse the MND (n=15) and control groups (n=15) scores separately 
(Bujang et al., 2018). The Cronbach’s alpha results demonstrated that the internal consistency 
of E-Motion and E-Motion subscales was variable and may be improved by removal of specific 
items. Research suggests that for smaller scales of less than ten items, Cronbach’s alpha may 
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underestimate the internal consistency of scales (Taber, 2018). These results should, therefore, 
be interpreted with caution as the subscales analysed had a low number of items. Further testing 
of E-Motion with a larger sample of neurotypical participants, more representative of the wider 
population, should be carried out before removal of items from the scale. This would ensure the 
Cronbach’s alpha analysis is more accurate and that subsequent removal of items results in the 
most internally consistent version of the E-Motion test. A formal pilot study with a large sample 
would enable further investigation of the internal consistency of E-Motion by emotion subscales 
(happiness, sadness, anger, fear), movement subscales (walking, lifting, knocking, throwing) 
and phase subscales (full figure, line figure and point light conditions).   
 
Another limitation of this study is that the increase in familywise error rate across the statistical 
analyses was not controlled for using Bonferroni correction or a false discovery rate controlling 
procedure (Cabin & Mitchell, 2000). Effect sizes and confidence intervals were, however, 
calculated to provide indicators of the magnitude of our findings. The difference between groups 
on E-Motion (p=0.001) remains significant when considering a more conservative significance 
level (p=<0.01). The results of this study are, however, preliminary and future research must be 
undertaken before concluding that individuals with MND may have any deficts in understanding 
emotional body language. 
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Appendix B Systematic Review Search Strategy 
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Appendix C Systematic Review PRISMA Flow Chart 
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Appendix D Systematic Review Quality Rating Scale 
QAS-MND (Adapted from SIGN Case-Control Studies Assessment Scale) 
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Appendix E MRP proposal 
 
Title: Major Research Project Proposal  
Investigating the Perception of Emotion Portrayed Through Body Movements in Motor Neuron 
Disease 
Abbreviated Title of Project:  E-Motion  
Base: Institute of Neurological Sciences, Queen Elizabeth University Hospital 
 
Principal Investigator Name: Iona Walker, Trainee Clinical Psychologist 
 
Academic Supervisor: Professor Jon Evans, Professor, University of Glasgow 
 
Field Supervisor:  Dr Steven Meldrum, Clinical Neuropsychologist  
 
Version: 2    Date: 26th May 2018  
 
BACKGROUND 
Motor Neuron Disease                                                                                                
Motor Neuron Disease (MND) refers to a group of disorders caused by a degeneration of the 
upper motor neurons in the cortex and or involving the lower motor neurons located in the brain 
stem and spinal cord (Desai  Joy, 2000; Talbot, 2009).The disease disrupts signals between the 
brain and the muscles causing progressive weakness, physical disability and speech difficulties. 
The average age of onset for MND is 56 years, with a typical prognosis of between two and five 
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years (Talbot, 2009).  The disease is fatal, most commonly due to progressive failure of the 
respiratory and cardiovascular systems (Talbot, 2009). 
 
Theory of Mind and the Mirror Neuron System  
Theory of Mind (TOM) refers to the ability to empathise and to understand that others have 
internal experiences different to one’s own (Baron-Cohen, 1991). Mirror neurons are a proposed 
set of specialised neurons activated either when an individual performs a particular motor act or 
observes another person performing a motor act (Di Pellegrino et al, 1992).  It has therefore, 
been suggested that a hypothesised Mirror Neuron System (MNS) enables people to learn how 
to infer other people’s mental states, through imitation and observation of facial expressions and 
body movements (Dapretto et al, 2006).  
 
In a recent study, experimenters gained consent to observe MNS activity in a group of epilepsy 
patients via intracranial depth electrodes which had been implanted to identify affected tissue 
prior to surgery (Mukamel et al, 2010). This pioneering research is the first to directly record 
activity of these neurons and has provided the most compelling evidence to date for the existence 
of the human MNS. The study demonstrated areas of the hippocampus and motor cortex showed 
excitation during the execution and observation of action and emotional expressions. 
Neuroimaging studies have also implicated neurons within the pars opercularis of the inferior 
frontal gyrus (inside Broca’s area) and the rostral posterior parietal cortex (Vigneswaran et al, 
2013; Dapretto et al, 2006). It has been proposed that damage to the MNS may underlie deficits 
in TOM associated with various disorders, including Autism (Pickett & London, 2005). 
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Social Cognition in MND 
Approximately 50% of MND patients develop cognitive impairment with an estimated 15% of 
individuals meeting the criteria for Frontotemporal dementia (FTD) (Bak, 2010). FTD is a 
progressive condition associated with memory difficulties, disinhibited behaviour and TOM 
deficits. A review of the literature concluded that people with MND may have deficits in TOM 
in terms of recognition of facial expressions, understanding of verbal expressions and 
interpretation of others intentions (Sedda et al, 2014).  More specifically research suggests MND 
patients show impairments on the Judgement of Preference Task (Girardi et al, 2011), the 
Reading the Mind in the Eyes test and the Faux Pas test (Meier et al, 2010). Further research 
has also suggested that social communication and understanding can be impaired in MND 
(Cavallo et al, 2011; Cerami et al, 2014; Watermeyer et al, 2015). Indeed, poor social awareness 
is a significant cause of distress for family members caring for MND patients (Merrilees et al, 
2010). It has been argued that MND patient’s poor performance on TOM tests is related to 
underlying executive dysfunction, rather than a specific deficit in social cognition.  Evidence 
suggests that TOM deficits correlate with impaired executive function tasks and as such may be 
caused by more general executive dysfunction (Gibbons et al, 2007; Burke et al, 2016).  A recent 
study by Girardi et al (2011), however, demonstrated patients with MND showed social 
cognition deficits on the Judgment of Preference Task, in the absence of executive dysfunction. 
It is therefore likely that MND causes a TOM deficit “over and above a deficit in executive 
functions” (Cavallo et al, 2011).  
 
Motion Perception and Social Cognition in MND  
Humans have evolved to deduce the internal states and emotions of others from facial 
expressions and body movements (Gelder, 2006). Biological motion perception refers to the 
human ability to identify and interpret the movement of living organisms and is thought to have 
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evolved for the purposes of survival and social interaction (Atkinson et al, 2007). Experiments 
have shown that point light displays conveying biological motion provide adequate information 
for participants to ascertain the action, gender and emotional state of the figure (Johansson 1973, 
Cutting & Kozlowski 1977; Mather & Murdoch, 1994, Brownlow et al, 1997). Lule et al (2007) 
reported that compared to controls, MND patients show reduced activation in the right middle 
temporal lobe, an area associated with the understanding of biological motion. Furthermore, 
individuals with MND appear to be impaired in terms of visualizing actions (Fiori et al, 2013) 
and understanding verbs and action words (Bak and Hodges, 2004; Grossman et al., 2008). A 
recent experiment used point light movies to depict an actor walking and conveying five 
different emotional states: happiness, sadness, neutral, anger, and fear (Chouchourelou et al, 
2006). A similar paradigm could be used to ascertain whether MND patients’ abilities to deduce 
emotion from physical movement are impaired.  
 
METHODS 
 
Aims & Hypothesis 
The current study aims to ascertain whether the perception of emotion portrayed through body 
movements is impaired in MND compared to the neurotypical population. The primary 
hypothesis predicts that the MND group’s mean score on the E-Motion, test, will be significantly 
different to the control group’s scores. The null hypothesis predicts that there is no significant 
difference between mean scores on the E-Motion test for the MND group and the control group.  
 
Power Analysis  
An a-priori power analysis was conducted using G*Power software (Faul & Erdfelder, 2007). 
The interpretation of emotion through body movements has not yet been explored in MND, 
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however, a related study reported that individuals with MND performed significantly poorer on 
a test requiring the interpretation of facial expressions compared to control groups (Oh et al, 
2016), with an effect size of .80. It is anticipated that a sample of 15 people with MND could 
be recruited to the present study, though a larger sample will be recruited if possible. With power 
at .80 with an alpha of .05, this would enable an effect size of .93 to be detected. Although this 
is a larger effect size than that found by Oh et al. (2016) the test used in this research should in 
theory be capable of detecting more subtle deficits. Rather than interpreting emotions portrayed 
by stereotyped and commonly known facial expressions (Oh et al, 2016), participants in the 
current study will be required to deduce emotions conveyed through more subtle body 
movements. The current study is, therefore, likely to be more sensitive to detecting impairments 
in social cognition.  
 
Participants 
Sample Size 
We aim to recruit 20 participants per group if possible. This is to account for high drop out rates 
in this area of research, due to significant physical deterioration associated with the disease. We 
aim to recruit spouses of MND patients for the corntol group.  For many of the control 
participants, carer burden may be high and as such we anticipate that drop out rates from the 
control group may also be high. We therefore, aim to recruit 20 people for the control group 
additionally.   
 
Inclusion and Exclusion Criteria 
Participants diagnosed with other psychiatric or neurological disorders including Frontal 
Temporal Dementia or who have a history of substance misuse will be excluded from taking 
part as control participants or as particpants in the MND group. In order to meet the inclusion 
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criteria, participants in the MND group will be fluent in English, over the age of 18 and have a 
diagnosis of MND. Neurotypical controls, fluent in English, over the age of 18 with no history 
of substance misuse, neurological or psychological disorder will be eligible to take part in the 
control group.  
 
Recruitment of The MND Group 
Participants with MND will be invited to take part through specialist MND Nurses at the Queen 
Elizabeth University Hospital (QEUH) Institute of Neurological Sciences. The specialist MND 
nurses will provide an initial study information sheet and contact details for the lead researchers. 
Should patients be interested to take part, they will contact the lead researcher directly to arrange 
a time to meet.  There will be at least two days between the date the MND nurse provides the 
information sheet and the date of the first meeting to allow participants to consider whether they 
wish to take part. At the first meeting the lead researcher will discuss the study information sheet 
again and answer any questions. At this first meeting informed consent will be taken for those 
who wish to take part. Should participants wish to start testing that day, the assessment will be 
initiated.  
 
Participants with MND will also be recruited via The Scottish MND Register, affiliated with 
the charity MND Scotland. The Scottish MND Register was set up to enable MND patients 
resident in Scotland to influence care services provided by Scottish health boards and local 
authorities. MND patients who have opted into the Scottish MND register can influence services 
through involvement in audit and research projects. Individuals who have opted to sign up to 
the Scottish MND register, provide consent for NHS researcher to invite them to take part in 
MND research studies. Participants on the MND register with addresses in the Scottish 
Highlands, Western Isles, Lanarkshire and Greater Glasgow and Clyde Health Board areas will 
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not be invited to take part via the MND register, as these areas are covered by the QEUH and 
these patients will already have been invited by their MND nurses to take part. Participants on 
the MND register with addresses in Ayrshire, Forth Valley, Fife, Lothian and Lanarkshire will 
be invited to take part via an invitation letter and study information sheet. Prospective 
participants with MND will, therefore, only be invited to take part in the study once.  Patients 
on the MND register with addresses in the Scottish Borders, the Isle of Arran, Dumfries and 
Galloway, Grampian and Tayside will not be invited to take part as the distance of travel for the 
main researcher to the visit the patients in their homes would be unfeasible given the time period 
of the study. It is also deemed too demanding for patients from these areas to travel to Glasgow 
for testing at the QEUH or Gartnavel Hospital due to the distance involved and the physically 
disabling nature of MND.  
 
Participants on the MND register who have addresses in Ayrshire, Forth Valley, Fife, Lothian 
and Lanarkshire will be invited to take part via a study information sheet and invite letter posted 
to them. This will be arranged through Shuna Coville, Director of the MND register who has 
agreed that the current study would be eligible following ethical approval. MND participants 
recruited via the register will contact the researcher via the details on their letter, should they 
wish to take part and a face to face meeting will be organized.  There will be at least two days 
between the MND patients contacting the researcher and the date of the first meeting to allow 
the participants to consider whether they wish to take part. At the first meeting the lead 
researcher will discuss the study information sheet again and answer any further questions. At 
this first meeting informed consent will be taken for those who wish to take part. Should 
participants wish to start testing that day, the assessment will be initiated. 
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Recruitment of Control Participants 
In order to match the MND group to the control group as closely as possible in terms of age and 
education, the researchers will aim to recruit spouses of MND patients who are participating in 
the research.  
 
Specialist MND nurses at the QEUH have contact with spouses who care for their relatives with 
MND. The MND nurses will invite spouses of MND patients  to take part in the study as control 
participants and will provide study information sheets with the contact details of the researcher. 
Control participant’s who wish to take part will contact the researcher and arrange a face to face 
meeting.  There will be at least two days between the prospective participant contacting the 
researcher and the date of the first meeting to allow the participants to consider whether they 
wish to take part. At the first meeting the lead researcher will discuss the study information sheet 
again and answer any further questions. At this first meeting informed consent will be taken for 
those who wish to take part. Should participants wish to start testing that day, the assessment 
will be initiated. 
 
Letters sent to those on the MND Register with addresses in Ayrshire, Forth Valley, Fife, 
Lothian and Lanarkshire, will also state that MND patients spouses may contact us to take part 
as control participants should they wish to be involved. Control participants recruited via the 
MND register will contact the researcher via the details on the letter. Should they wish to take 
part a face to face meeting will be organized.  There will be at least two days between the 
participant contacting the researcher and the date of the first meeting to allow the participants 
to consider whether they wish to take part. At the first meeting the lead researcher will discuss 
the study information sheet again and answer any further questions. At this first meeting 
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informed consent will be taken for those who wish to take part. Should participants wish to start 
testing that day, the assessment will be initiated. 
 
A poster will also be placed in waiting areas in Neurology and Neuropsychology Clinics, 
recruiting control participants without any neurological difficulties. 
 
Informed consent 
Explaining the study, answering any questions and signing the consent form is estimated to take 
approximately 10 minutes. 
 
Background Measures  
In order to obtain an estimated premorbid IQ the Test of Premorbid Functioning (TOPF) which 
takes approximately five to ten minutes, will be administered to all participants (Wechsler, 
2011).  
 
Cognitive Screening 
Social intelligence may be affected by cognitive deficits. As such, the sample will also complete 
the Edinburgh Cognitive and Behavioural ALS Screen which takes approximately 30 minutes 
(ECAS) (Niven et al, 2015), to provide a measure of cognitive difficulties and executive 
dysfunction.  
 
Psychological Assessment 
Affective disturbance may also influence participants’ performance on tests of emotional and 
cognitive abilities. Subsequently control subjects will complete the Hospital Anxiety and 
Depression Scale and the patient group will be provided with a version of adapted for use with 
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MND patients (HADS-M) both of which take approximately five minutes to administer 
(Gibbons et al, 2011).  
 
Baseline Motor Skills 
Both groups will also be asked to replicate a range of transitive and intransitive pantomime 
actions, which will take approximately 10 minutes, as a measure of the ability to interpret basic 
movements in the absence of emotional cues.  
 
Test of Social Awareness 
Subjects will be asked to complete subtests of The Awareness of Social Inference Test (TASIT, 
McDonald et al, 2003). This test requires participants to identify happiness, sadness, anger, 
anxiety and neutral emotion from videotaped social scenes and will take approximately 10 
minutes to administer.  
 
Test of the Perception of Emotional Body Gestures 
Both groups will also complete the E-Motion test, a new thirty-five minute assessment tool 
created for the study, which involves identifying five key emotions portrayed through body 
movements. E-Motion video recordings show an individual portraying happiness, sadness, 
anger, anxiety and neutral emotion, through body movements without additional verbal cues or 
facial expressions.  
 
Data Management & Analysis  
Data will be stored in a secure password protected spreadsheet, in line with data protection 
regulations. Participants will be registered on a list with their names and ID numbers. Participant 
names will not be recorded on paper records, their ID numbers will be noted on paper records. 
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Names and signatures of participants will be on consent forms. Paper records containing 
participant numbers, demographic information and each participant’s responses on the tests will 
be kept in a locked cupboard at the QEUH MND Research room. The consent forms with patient 
names will be kept in a separate locked cupboard in the QEUH MND research room. The 
Anonymised data set will be input into a excel spreadsheet on an NHS computer in the QEUH 
research room. This will then be uploaded to a secure password protected encrypted memory 
stick. Analysis of the anonymised data will be done on a University computer (with access to 
SPSS). In order to protect the identity of patients with MND, age rather than date of birth will 
be used in the anonymised data set. At end of project Jon Evans will be the custodian of the 
data. He will keep the psuedonomysed data in a locked cabinet in his office at the Gartnavel 
Administration Building for 10 years, following which it will be destroyed.  
 
Assuming parametric assumptions are met, the data will be analysed using an independent T- 
test on SPSS to ascertain whether there is a statistically significant difference between the 
control and MND group’s means on the E-Motion test. If the data does not meet parametric 
assumptions, then a Mann Whitney U test will be used.  The relationship between social 
cognition tests and factors will be explored using Pearson’s or Spearman’s correlation 
depending on the normality of the data. 
 
Settings and Equipment 
MND patients often receive home visits from MND nurses and occasionally attend hospital for 
clinically necessary procedures. Due to the physical debilitation associated with MND, patients 
are often unable to travel, as such home visits will be offered to participants with MND who are 
unable to attend the QEUH or Gartnavel Hospital. 
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Control participants will have the option of being seen at the Mental Health and Wellbeing 
Centre at Gartnavel Hospital or at a research room at the QEUH. Additionally in cases where 
the control participant is the partner of a MND patient taking part in the study and the researcher 
is visiting their relative with MND at home to undertake the testing, the control participant (carer 
for the MND patient) will also be offered to be seen in their home, and to be tested in succession, 
following their partner. The rationale for this is to minimise travel costs which NESS will be 
refunding and disruption to families taking part in the study.   
 
Ethical and Health and Safety Issues  
For participants with MND being seen at the QEUH MND service, we may request to share 
information between our research team and their clinical care team regarding results of some of 
the tests. This is because some of the questionnaires and cognitive tests used in this study 
(HADS-M & ECAS) are routinely delivered at the QEUH MND service and as such by 
communicating with the QEUH team,  we would prevent the participants from repeating any 
tests they have already undertaken. 
 
Domiciliary visits are necessary to recruit participants with MND who may be housebound due 
to progressive physical disabilities. Precautions will be taken to mitigate risks and the University 
of Glasgow (2018) and NHS Greater Glasgow and Clyde (2012)  Lone worker policies will be 
followed (see appendix G).  The researcher will apprise themselves of the risk assessment by 
the clinical team at the QEUH. For participants being visited in their homes, recruited from the 
MND register, the invite letter will explain that in order to take part in the study participants 
must consent to the main researcher contacting the MND nurse involved in their care. This will 
enable the main researcher to contact the patients MND nurse to apprise themselves of the risk 
assessment and ensure the patient is suitable to be visited in their home.  Should the main 
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researcher have any concerns regarding the safety of the MND patient or regarding their home 
environment these concerns will be passed on to the MND nurse in their care.  
 
It is important to consider that participants with MND may be suffering from pain and fatigue. 
Including information giving, consent taking, the testing session and debriefing, the study will 
take approximately one hour forty five minutes. Breaks will be offered and participants will also 
be given the option to complete the testing over two sessions. With regards to travel expenses, 
as discussed it is likely that the majority of participants will be seen in their homes, particularly 
for MND participants who live further away. Some patients living within Greater Glasgow and 
Clyde or the Edinburgh region may wish to be seen at the QEUH or Gartnavel Hospital.  For 
those who drive the cost of petrol is estimated to be around 16 pounds for a return trip and to be 
13 pounds on public transport. Expenses will be offered for those who opt to travel to the QEUH 
or Gartnavel.   
 
The study is funded by NHS Education for Scotland. The results will be disseminated via the 
University of Glasgow Special Collections Thesis Website and may be presented in a Poster 
presentation at conferences. We also intend to publish the study in a relevant journal. All 
information published will be anonymous. Should they opt into this,  all participants will be sent 
a letter following the study to notify them of the results.  
 
Practical Applications  
This research has the potential to improve our understanding of social difficulties associated 
with MND and how to support patients with this. Furthermore, this study may also provide 
evidence regarding whether the putative MNS is compromised in MND.   
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Appendix G MRP Health & Safety Form 
UNIVERSITY OF GLASGOW 
DOCTORATE IN CLINICAL PSYCHOLOGY 
HEALTH AND SAFETY FOR RESEARCHERS 
 
 
1. Title of Project Investigating the Perception of Emotion Through 
Body Gestures in Motor Neuron Disease  
2. Trainee Iona Walker 
3. University Supervisor Professor Jon Evans 
4. Other Supervisor(s) Dr Steven Meldrum 
5. Local Lead Clinician Dr George Gorrie 
6. Participants:  (age,  group or sub-
group, pre- or post-treatment, etc) 
Age 18 or over patients with Motor Neuron 
Disease & neurotypical controls.  
7. Procedures to be applied  
(eg, questionnaire, interview, etc) 
 
Questionnaires 
Cognitive Testing  
8. Setting (where will procedures be 
carried out?) 
i) Details of all settings 
Patients homes  
 ii) Are home visits involved  YES 
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9. Potential Risk Factors Considered 
(for researcher and participant 
safety): 
i) Participants 
ii) Procedures 
iii) Settings 
 
 
 
 
This particular client group (Motor Neuron 
Disease patients) are not normally associated with 
dangerous or aggressive behaviour. This is due to 
physical disability caused with the condition.  
Participants with Motor Neuron Disease may be 
emotionally labile.  
Procedures (questionnaires and cognitive testing) 
are non-invasive, but may be cognitively 
demanding. 
In terms of the setting, due to their debilitating 
condition, patients with MND will be tested in 
their individuals homes so as to avoid the added 
distress of travel and mobility difficulties. As 
such, possible health and safety issues for 
participants and researchers may arise. Control 
participants who do not have any physical 
problems will be tested at the Queen Elizabeth 
University Hospital, where the environment is 
designed to be safe for clinical use.  
10.  Actions to minimise risk (refer 
to 9)  
i) Participants 
ii) Procedures 
iii) Settings 
 
 
 
 
 
 
i) Participants  
Participants with MND will be in their own 
homes, so any risks identified in this setting will 
be raised with supervisors and the patient's 
clinical nurse specialist who would take any 
required actions.  
ii) Procedures  
Procedures are non-invasive and cognitive 
screening and psychological questionnaires 
administered would be administered during the 
course of patients’ assessment at the QEUH MND 
service as standard. The only additional test 
employed is the new perception of emotion DVD 
made by our researchers and subtests of the 
TASIT. These tests are not designed to be and do 
not tend to be distressing, but should participants 
become distressed, testing will be stopped. Details 
of what the study entails will be provided before 
testing and it will be made clear that participants 
can opt out at any time. Details for psychological 
support organisations will be provided at the end 
of each session. To minimise the risk of people 
becoming fatigued, individuals will be offered 
breaks.  
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Settings  
In terms of settings, being in patients’ homes may 
present certain risks to the researcher. This 
potential risk will be mitigated by the researcher 
communicating the location and time of all home 
visits to supervisors and checking in at the end of 
each session. Additionally, the researcher will 
carry a personal alarm and a mobile phone at all 
times. 
It is not possible to see the participants in the 
staffed facility and there is a significant risk of 
sampling bias if participants requiring home visits 
were excluded from the study. Many patients with 
MND have significant disabilities which mean 
that they would be unable to attend the QEUH.  
All participants will have had contact with a 
member of the clinical team at the QEUH 
involved with the patient and a risk assessment 
carried out. Patients without risk assessments will 
not be eligible for home visits.  
As the trainee I will apprise myself of the risk 
assessment in all cases prior to the visit. 
As the trainee I will discuss potential for risk with 
a member of the clinical team who has had 
contact with the patient recently.  
As a result of 3 and 4 the risk to myself as the 
trainee is deemed to be low. I will discuss any 
doubts or concerns about any particular patients 
with the University supervisor and/or a senior 
member of the clinical team that have 
responsibility for management of the patient. 
The overall appraisal of risk for each patient will 
take into account what is known about the 
participant, a risk assessment of their living 
environment by the clinical team and 
consideration of the geographical siting of the 
visit. This will include assessment of any risk 
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Trainee signature:                                                                 Date: 15/01/2018 
 
 
University supervisor signature:                 Date:28/01/2019 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
associated with travelling to and from the 
participant’s home.  
Home visits will be conducted in normal work 
hours. 
The lone worker policy for the QEUH and GGC 
will be followed. 
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Appendix H MRP Participant Information Sheet 
Participant Information Sheet  Version 3 Date 29th July 2018  IRAS Project ID: 237392 
Study Title: Investigating the Perception of Emotion Portrayed Through Body Movement in 
Motor Neuron Disease 
Dear Prospective Participant,  
 
My name is Iona Walker, I am a Trainee Clinical Psychologist, studying at the University of Glasgow 
and working in the NHS. As part of my doctoral training to become a Clinical Psychologist I am 
conducting research to understand more about Motor Neuron Disease and the effects this condition has 
on emotion perception.  This research is supervised by Professor Jon Evans at the University of 
Glasgow and Dr Steven Meldrum, Clinical Psychologist at the Queen Elizabeth University Hospital 
(QEUH). Before you decide whether you would like to take part,  please take the time to read the 
information below about why the research is being conducted and what it would involve for you. 
Please don’t hesitate to contact us if you have any questions or would like more information. 
 
Why are we conducting the research?  
Recent research suggests that MND may affect people’s ability to perceive other people’s emotions.  
To date research has not yet explored whether people with MND have difficulties interpreting 
emotions portrayed by body movements. The current study aims to investigate whether MND affects 
the ability to interpret emotional body language. This research has the potential to improve our 
understanding of social difficulties people with MND may face. The study will involve people with 
MND and people who do not have any neurological conditions.  
 
Who is able to take part?   
We are inviting participants who have a diagnosis of Motor Neuron Disease (MND) to take part. We 
are also inviting partners of people who have MND, who do not have any neurological conditions, to 
take part in the study as a comparison group, often known as the control group.  
In order to take part, participants with MND will be fluent in English, over the age of 18 and have a 
diagnosis of MND. In order to take part, participants in the control group must be fluent in English, 
over the age of 18 with no history of substance misuse, neurological or psychiatric disorder. 
Participants diagnosed with other psychiatric or neurological disorders or who have a history of 
substance misuse are not able to take part in the MND group or control group.  
Do I have to take part? 
No, it is up to you to decide.  Even if you say yes now, but later change your mind, you can do so 
without giving a reason and without your medical care being affected now or in the future. 
What would taking part involve? 
Participants can be visited in their homes to complete the study, or alternatively should you wish to be 
seen in a clinical venue, you can be seen at the Queen Elizabeth University Hospital (QEUH) or 
Gartnavel Royal Hospital Administration Building.  
At the first session, the researcher will explain what the study involves and give you an opportunity to 
read through the information sheet and ask any questions, before asking whether you wish to take part. 
If you wish to take part, you will be asked to sign a consent form. If you should wish to start testing at 
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this first session, we can do so. If you would rather arrange a separate time to complete the testing this 
is also an option for you. This initial step of gaining informed consent may take fifteen minutes.  
The study involves completing a questionnaire about anxiety and low mood and cognitive tests which 
examine skills such as social perception and memory.  Participants will also be asked to complete a test 
which involves interpreting the emotion portrayed through body movements. Including gaining 
consent, administering the tests and debriefing after the session, this will take approximately one hour 
45 minutes. This can be completed with breaks in between or over two sessions, depending on 
individual preference. 
Please note that for patients with MND, in order to take part in the study, you must consent to our 
research team having contact with your MND Nurse Specialist. The reason for this is to ensure we 
have the means to communicate with a professional involved in your care, should any concerns about 
your health or wellbeing arise.  
You may leave the study without completing the questionnaires or tests without providing a reason at 
any time.  
Will I receive Expenses? 
There are no direct benefits to taking part in the study and participation is voluntary. Travel expenses 
to and from the QEUH or Gartnavel can be applied for, unless the participant is visited in the home. 
Are there any risks associated with the study? 
The study is non-invasive in nature and involves pen and paper based tests and watching videos. 
Responses will be recorded in writing by the Trainee Psychologist and the participant will not be 
required to write, although a signature on the consent form will be required. Please note that should 
information arise during the course of the study which should indicate that you are at risk in any way, 
the researcher will contact your MND nurse on your behalf to pass on any concerns. For control 
participants, who do not have an MND nurse, should you raise concerns that you require support, 
details will be provided of appropriate organisations to access support.  
What will happen to the information I give? 
Anonymised participant information will be stored in the MND QEUH service in a locked room, 
uploaded to a secure database on a secure NHS computer and all original copies destroyed 12 months 
after the study. Anonymised data in a password protected spreadsheet will be stored in a memory stick 
in a locked cabinet at Glasgow University and destroyed after 10 years.  
 
This study will be written up as part of my University Thesis. It is hoped that this study will be 
published in a journal at the end of the study and presented at a conference in a poster presentation. All 
information used in the published literature would be completely anonymous. A summary of findings 
will also be sent to all participants who would like us to do so. Please note that identifiable data from 
the study may be accessed by representatives of the study Sponsor, NHS Greater Glasgow &Clyde, for 
audit purposes.  The anonymised data may also be shared with other researchers for use in future 
approved research studies.  
 
For participants with MND being seen at the QUEH MND service, we may request to share 
information between our research team and your clinical care team regarding results of some of the 
tests. This is because some of the questionnaires and cognitive tests used in this study are administered 
at the QEUH MND service as part of your routine care and as such by communicating with the QEUH 
team, we would prevent you from repeating any tests you have already undertaken. 
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NHS Greater Glasgow and Clyde is the sponsor for this study based in Scotland. We will be using 
information from you in order to undertake this study and will act as the data controller for this study. 
This means that we are responsible for looking after your information and using it properly. NHS 
Greater Glasgow and Clyde will keep identifiable information about you until the study is completed. 
Your rights to access, change or move your information are limited, as we need to manage your 
information in specific ways in order for the research to be reliable and accurate. If you withdraw from 
the study, we will keep the information about you that we have already obtained. To safeguard your 
rights, we will use the minimum personally-identifiable information possible. You can find out more 
about how we use your information by contacting the researcher.  
 
NHS Greater Glasgow and Clyde will keep your name and other identifiable information confidential 
and will not pass on this information.  NHS Greater Glasgow and Clyde will use this information as 
needed, to contact you about the research study, and make sure that relevant information about the 
study is recorded for your care, and to oversee the quality of the study. In the event that the study is 
audited, NHS Greater Glasgow and Clyde and regulatory organisations may review identifiable 
information to check that the informed consent process was followed and to check the accuracy of the 
research study. With the exception of auditing, no identifiable information will be shared with anyone 
outwith the research team. 
  
 
What if something goes wrong? 
 
We do not anticipate any problems with this study, however, please don’t hesitate to contact the 
researcher with any queries or concerns. If you wish to complain, or have any concerns about any 
aspect of the way you have been approached or treated during your participation in the research study 
NHS GGC complaints procedure are available to you. As this study is sponsored by NHS GGC 
individuals participating as either control participants or as part of the Motor Neuron Disease group, 
may register concerns or complaints with NHS GGC.  
 
To register a complaint through NHS Greater Glasgow and Clyde please contact 0141 201 4500. You 
can also call the NHS Patient Advice and Support Service PASS should you require further advice or 
support about how to register a concern or a complaint on 0800 917 2127. Lines are open Monday-
Friday, 9am-5pm. You can find more information about PASS on the website at www.cas.org.uk/pass. 
 
How do I ask for more information or opt into take part?  
Participation in this study does not affect any aspect of routine clinical care. If you would like more 
information or to take part in this study please contact Iona Walker, the main researcher by email: 
i.walker.1@research.gla.ac.uk  or by Phone: 07971570999. Professor Jonathan Evans and Dr 
Steven Meldrum are supervising the project. (email: Jonathan.Evans@glasgow.ac.uk; 
Steven.Meldrum@ggc.scot.nhs.uk). If you make contact with us, we will offer to arrange a time 
convenient to you to discuss the study further and obtain your consent to partake, by visiting you at 
home or by arranging an appointment at the Queen Elizabeth University Hospital or Gartnavel 
Hospital, depending on your individual preference.  
Yours sincerely, 
 
Trainee Clinical Psychologist  
NHS Greater Glasgow and Clyde 
 
Thank you for reading this Information Sheet 
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Appendix I MRP Consent Form 
Version 3 Date 29th July 2018 IRAS Project ID: 237392 
Participant Identification Number for this trial: 
Study Title: The Perception of Emotion Portrayed Through Body Movements in Motor Neuron 
Disease 
Name of Researcher: Iona Walker  
                                        Please initial the boxes 
                                                                                                                         Yes       Not Applicable  
1. I confirm that I have read the information sheet dated 29th July  
(version 3) for the above study. I have had the opportunity to  
consider the information, ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical 
care or legal rights being affected. 
 
3. I understand that the information collected about me will be used to  
support other research in the future, and may be shared anonymously  
with other researchers. 
 
4. I agree to any necessary exchange of information about me between 
 my MND Nurse and the research team. 
                                                                                                                                              
5. I give permission for my data to be looked at by 
representatives of the study Sponsor, NHS GG&C, for audit 
purposes.  
 
6. *This question pertains to participants with MND who are being seen 
at the Queen Elizabeth University Hospital.  
I understand that relevant sections of my medical notes and data collected 
during the study, may be shared between the researchers of this study and 
the clinical staff at the MND Service at the Queen Elizabeth University 
Hospital.  
 
7. I agree to take part in the above study.  
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Name of Participant  Date    Signature 
 
 
 
            
Name of Person  Date    Signature 
taking consent 
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Appendix J MRP Debrief Form 
 
STUDY DEBRIEF FORM  Version 2 Date 26th May 2018 IRAS Project ID: 237392 
Study Title: The Perception of Emotion Portrayed Through Body Movements in Motor Neuron 
Disease 
Dear Sir/Madam,  
We would like to sincerely thank you for taking the time to be a part of this research study to help us 
improve our understanding of Motor Neuron Disease (MND). 
What was the purpose of the research study?  
This study is part of my qualification in Clinical Psychology which I am undertaking at the University 
of Glasgow, in collaboration with NHS Greater Glasgow and Clyde. I am supervised by Professor 
Jonathan Evans at the University of Glasgow and Dr Steven Meldrum at the Queen Elizabeth 
University Hospital. Recent research suggests that MND may affect people’s ability to perceive other 
people’s emotions.  To date research has not yet explored whether people with MND have difficulties 
interpreting emotions portrayed by body movements. The current study aims to investigate whether 
MND affects the ability to interpret emotional body language. This research has the potential to 
improve our understanding of social difficulties people with MND may face. The study will involve 
people with MND and people who do not have any neurological conditions.  
What happens to the results and the data you have collected about me?  
Information collected in this study is anonymised. Anonymised data from this study may be shared 
anonymously with other researchers for use in other approved studies. Identifiable  data may be 
looked at by representatives of the study Sponsor, NHS GG&C, for audit purposes. For participants 
with MND being seen at the QUEH MND service only:  as discussed, we may share information 
between our research team and your clinical care team regarding results of some of the tests. This is 
because some of the questionnaires and cognitive tests used in this study are routinely delivered at the 
QUEH MND service and as such by communicating with the QUEH team,  we would prevent you 
from repeating any tests you have already undertaken.  
 
Anonymised participant information will be stored in the MND QEUH service in a locked room, 
uploaded to a secure database on a secure NHS computer and all original copies destroyed 12 months 
after the study. Anonymised data in a password protected spreadsheet will be stored in a memory 
stick in a locked cabinet at Glasgow University and destroyed after 10 years.  
 
 
At the end of the study the research team aims to publish the results in a journal and present a poster 
at a conference. The study will also be submitted as part of my thesis on the Doctorate of Clinical 
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Psychology Course and may be uploaded to the Thesis Collection on the University of Glasgow 
Library Website.  
 
Who can I contact if I need to access support?  
If you have been affected by any of the issues discussed in the course of this research study, or are 
requiring support for reasons unrelated to this study, you can contact the organisations below for 
advice and support. If you require immediate help or would like a referral to an NHS service please 
contact your GP or if relevant your MND nurse.  
• For support related to living with MND, for people with MND and their carers: MND Connect 
Helpline: 0808 802 6262 or email:  mndconnect@mndassociation.org 
• For emotional support for mental health problems, SANEline is a national out-of-hours 
telephone: 0300 304 7000 
 
Thank you again for your time. Should you have any further questions about the study you can contact 
me by email: i.walker.1@research.gla.ac.uk 
I wish you all the very best for your future,  
Yours sincerely, 
 
Trainee Clinical Psychologist  
NHS Greater Glasgow and Clyde 
 
Thank you for reading this Debriefing Sheet 
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Appendix K MRP Research Cost & Equipment Form 
 
 
RESEARCH EQUIPMENT, CONSUMABLES AND EXPENSES  
 
Year of Course 2nd year Intake Year 2016 
 
 
Item 
 
Details and Amount 
Required 
 
Cost or Specify if to 
Request to Borrow from 
Department 
 
Stationary 
 
 
26 envelopes A4 
(1 per participant)  
2x sheets of labels 
(To enable 1 per 
participants to aid filing) 
0.94 
0.03 
 
Subtotal: 0.97 
 
Postage 
 
 
 
26 letters to post  
( 1 per participant)  
16.12 
 
 
 
 
Photocopying and Laser 
Printing  
 
260 pages of photocopying 
(10x per participant) 
52 sheets of printing  
(2x per participant)  
 
13.00 
2.60  
 
Subtotal: 15.60 
 
Equipment and Software 
 
NA  
 
:NA 
 
Measures 
 
 
Already available 
 
 
 
 
 
NA 
 
 
 
Miscellaneous 
 
 
Travel expenses for 
participants (this will be 
applied for on a case by 
case basis as participants 
will be offered to be seen in 
their homes, but have the 
option of asking to be seen 
in clinical space at the 
QEUH or Gartnavel 
Hospital)  
 
Travel expenses for the 
researcher will be refunded 
via the NHS GGC expenses 
website as part of the 
researcher’s usual 
employment.  
Based on a small 
percentage of our sample 
requesting to travel to a 
clinical setting. Travel 
expenses for 10 participants 
would cost an estimated: 
160 pounds.  (this estimate 
is based on car mileage 
cost). 
 
 
 
Total  192.69 
 
For any request over £200 please provide further justification for all items that contribute to a high 
total cost estimate. Please also provide justification if costing for an honorarium: 
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Trainee Signature:                                         Date: 11th June 2018 
 
Supervisor’s Signature :                              Date: 11th June2018 
 
 
 
 
 
Appendix L Development of E-Motion Task 
 
Development Phase 1 Conception  
• The idea for the E-Motion task emerged from discussions between Iona Walker, 
Trainee Clinical Psychologist, Professor Jon Evans and Dr Steven Meldrum relating to 
recent research findings that individuals with Motor Neuron Disease (MND) can 
develop difficulties with ToM in the course of the illness. The hypothesized 
relationship between mirror neurons and ToM  was discussed and it was noted that it 
may be valuable to understand whether the ability to discern emotions from body 
movements (an ability associated with mirror neurons) may be impaired in the course 
of MND. 
• The idea of developing a novel test aiming to measure people’s ability to discern 
emotions from body movements to investigate this in the MND population in 
comparison to a control group was discussed. 
• It was noted that it would be necessary to obscure facial expressions to ensure the test 
isolated the ability to understand emotion through body movements, rather than 
through other cues.   
• It was suggested that the name of the proposed test be E-Motion.  
 
Development Phase 2 Preliminary Stimuli Selection  
• Ma, Paterson & Pollick (2006) had previously developed a body movement library to 
capture many different aspects of human movement, including emotion. The 
movements of 30 individuals (15 male, 15 female) were captured using body sensors 
whilst they walked, knocked, lifted and threw whilst wearing sensors and were asked 
to depict happiness, sadness, anger or fear through their movements.  
• Details of this library are accessible here: Ma, Y., Paterson, & Pollick, F.E. (2006). A 
motion-capture library for the study of identity, gender, and emotion perception from 
biological motion. Behavior Research Methods, Instruments, & Computers, 38, 134-
141. 
• Professor of Psychology, Frank Pollick and Mr Hyuga Tanimoto, Computer 
Programmer at the University of Glasgow were contacted regarding using data from 
the motion capture library (Ma, Paterson & Pollick, 2006). Stimuli showing people 
knocking, lifting, throwing and walking depicting happiness, sadness, fear and anger 
for use in a proposed new test of understanding emotions through body movements 
were requested.   
• Hyuga Tanimoto, Computer Programmer, supervised by Professor Pollick, selected 40 
stimuli from the motion capture library in “full figure” mode depicting happiness, 
sadness, anger and fear in a combination of knocking, throwing, lifting and walking 
actions. Stimuli were selected based on which videos they considered displayed the 
clearest movements as judged by Hyuga Tanimoto.  
• Full figures were gender neutral.  
• Character Studio (plug-ins for 3D Studio Max, AutoDesk Inc.) or Matlab (The 
Mathworks) or a combination of these two were used to convert the data into videos.  
• The 40 files in “full figure” format were transferred onto a PowerPoint presentation to 
enable the stimuli to be presented on a Mac computer.  
• It was decided that the format by which participants would provide responses to stimuli 
would be by selecting from one of four options presented in front of them -  “happy, 
sad, afraid or angry.” 
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• 10 people were recruited by Iona Walker via opportunity sampling. Five males and 
five females between the ages of 29-63 years (average age of 37.9 years) with no past 
or present neurological or mental health difficulties were shown the 40 full figure files 
using a power point presentation (see table L.1)   
• Each were tested individually and the ten participants chose from four emotions 
(happy, sad, afraid or angry) on a card in front of them.  
 
Development Phase 3 Item Selection  
• In order to ensure that we only included stimuli that could be classified with a 
reasonable level of consistency, we excluded stimuli which were correctly classified by 
less than 30% of participants. 
• Stimuli with 30% or higher pass rate were considered for inclusion in the final test and 
the best performing stimuli from each type of emotion and action subtype were 
selected. This ensured each movement and emotion pairing were equally represented in 
the final E-Motion test.  
• Where more than one stimuli demonstrating the same action and emotion pairing 
scored the same in % accuracy, the lead researcher (Iona Walker) chose the video 
which had the most exaggerated movement and therefore which was deemed to be the 
more discernible of the options.  
• Four of the highest rated “full figure” stimuli (in terms of % accuracy correct from the 
10 control participants) were selected for each emotion (happiness, sadness, fear and 
anger) comprising of throwing, lifting, walking and knocking movements. 
• This resulted in 16 “full figure” stimuli being selected for inclusion in the E-Motion 
test.  
• In the sample of 10 people testing the stimuli the mean accuracy for the chosen set of 
16 full figure stimuli was 66.90% (mean score 10.7). 
 
Development Phase 4 Final E-Motion Test Development 
• Hyuga Tanimoto developed the point light “dot” and “line” versions of the same 16  
full figure files selected from development phase 3 and sent them to Iona Walker for 
inclusion in the final set of stimuli.  
• The final test administered through a Power Point presentation featured 48 stimuli 
comprising of three phases of the same 16 stimuli: 1.full figure (n=16 stimuli); 2.point 
light line (n=16 stimuli); 3. Point light dot (n=16 stimuli) (See table L2 for order 
presented). 
• At the top right hand side of each slide the action type was noted, for example 
“walking.” The purpose of this design was to ensure the participants’ attention was 
focused on determining the correct emotion, rather than the action type. 
• Phase 1 only featured full figure stimuli. Within phase 1 the order of 16 stimuli was 
randomised to create the final test.  
• Phase 2 only featured point light “line” figures. Within phase 2 the order of 16 stimuli 
was randomised to create the final test. 
• Phase 3 only featured point light “dot” figures. Within phase 3 the order of 16 stimuli 
was randomised to create the final test.  
• All participants viewed the same stimuli in the same order. This entailed watching 
phase 1 full figure stimuli (n=16) showing happiness, sadness, anger and fear 
demonstrated through throwing, lifting, walking and knocking movements.  
Then watching phase 2 point light display line stimuli (n=16) showing happiness, 
sadness, anger and fear demonstrated through four movements throwing, lifting, 
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walking and knocking. Finally all participants watched phase three point light display 
dot stimuli (n=16) showing happiness, sadness, anger and fear demonstrated through 
four movements throwing, lifting, walking and knocking. 
• Participants provided the answer from four options from a card in front of them with 
the words printed happy, sad, angry, afraid.  
• Participants could point to the option if they had speech difficulties (commonly 
experienced by individuals with MND). Participants could verbalise their response if 
they had motor difficulties affecting hand movements (commonly experienced by 
individuals with MND).  
• Time of Test  
The test takes 35 minutes to administer including explanation prior to the beginning to 
the test and time to answer any questions.  Each stimuli takes approximately 30 
seconds at the end of which the participant has ten seconds to give their response.  
• Insight Rating  
Participants were also asked to rate their confidence in each answer they provided from 
0% indicating they were not certain at all to 100% indicating they were completely 
certain. Confidence ratings from 48 items were added and then the total was divided by 
48 to provide an average confidence rating for the E-Motion test.  
The actual % accuracy was then estimated (% of items correct out of 48). The actual % 
accuracy was deducted from the confidence rating to produce an insight rating (either 
positive or negative value depending on if confidence was overestimated or 
underestimated for each participant. This was designed with the aim of providing an 
estimation of an individual’s insight into their ability on E-Motion. 
For participants with speech difficulties (common in MND) a chart with 0-100% was 
displayed for them to choose the relevant percentage. For participants with motor 
difficulties affecting hand movements (common in MND) they were able to verbalise 
their answers.  
• Administration instructions  
The examiner read the below script to the examinee verbatim: 
E-MOTION is a new test which aims to investigate how we understand emotions 
through body movements. Actors/actresses were asked to act out four motor actions 
whilst portraying a particular emotion. Actors were asked to throw, walk, lift or knock 
in an angry, sad, happy or afraid manner. The actors/actresses performed these 
movements with sensors on them. Then this data was transformed into a computer 
generated figure doing the actions. We have obscured the face of the computer 
generated figure.  This is because the aim of this study is to understand how people 
perceive emotions through body movements rather than facial expressions. The bodies 
depicted are gender neutral. I will play you a series of videos which show computer 
generated figures portraying emotions through movements. There are three sets, the 
first a full body image, the second a “stick” figure and the third shows a figure 
represented by dots.  I will ask you after each trial how confident you are from 0-100% 
that your response was correct. As this is a new task we aren’t used to doing on a daily 
basis, it is normal to be uncertain or to find some of the videos difficult to decipher. 
You won’t receive feedback as to whether you are choosing the correct response. Just 
give it your best guess and select the emotion you think the video is closest to from 
these four options. Please note, I can only play each video once and cannot repeat the 
video. Do you have any questions?  If an individual has speech difficulties explain that 
they can also point to the preferred option. After every block provide verbal 
encouragement  “your concentrating well” “your half way” “Keep going.”  Participants 
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are presented with the four options on a card: AFRAID; HAPPY; SAD; ANGRY. How 
confident are you that your response is accurate? 0-100% 
Phase 5 E-Motion Study administered with individuals with MND (n=15) and further 
separate 15 control participants (n=15 controls)  
• In the main study the final E-Motion test comprising of 48 stimuli was administered to 
15 controls (see table L3 below). The mean accuracy for the 15 control participants 
was 70.81%  (mean score=11.33) at full figure stage,  65.00% for line phase (mean 
score=10.40) and 68.30% at dot stage (mean score=10.93). The total combined three 
phases of 16 trials each comprise the full E-Motion total score. The average E-Motion 
total score for the control group (n=15) was 68.06%. (mean score=32.67).  
• In the main study individuals in the MND group (n=15) completed the full E-Motion 
test (Table L4). The mean accuracy for the 15 participants who had MND was 60.81% 
at full figure phase (mean=28.53), 56.25% for the line phase of the test (mean 
score=9.00) and 61.25% at dot phase (mean=9.80). The scores from three phases are 
combined to produce the E-Motion total score. The MND group E-Motion total score 
was an average of 59.44% (average score=28.53). 
 
Table L1. Test Control Participants (n=10) % Accuracy on 40 Stimuli  
Stimuli 
Number/ 
(NS=not 
selected) 
Stimuli name % Accuracy 
16 Jua_knock_Afraid_1 70 
2 Jan_lift_afriad_2 30 
10 Jan_throw_afraid_1  60 
14 Jan_walk_afraid_2 70 
NS Jua_knock_afraid_2 60 
NS Lin_lift_afraid_1 30 
NS Lin_walk_afraid_1 60 
NS Mac_knock_afraid_1 40 
NS Pet_knock_afraid_1 60 
NS Jua_knock_afraid_1 50 
15 Jan_knock_Angry_1 90 
11 Boo_lift_angry_1 30 
7 Ali_throw_angry_2 100 
8 Chr_walk_angry_2 80 
NS Amc_knock_angry_1 90 
NS Bar_throw_angry_2 100 
NS Boo_throw_angry_2 90 
NS Chr_lift_angry_1 20 
NS Chr_throw_angry_1 90 
NS Chr_walk_angry_1 70 
5 Kat_Lift_happy_1 60 
12 Dav_knock_happy_1  70 
6 Ste_throw_happy_2  40 
1 Ale_walk_happy_1 100 
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NS Ale_lift_happy_2 50 
NS Ali_throw_happy_2 20 
NS Boo_knock_happy_1 60 
NS Boo_lift_happy_2 30 
NS Dav_knock_happy_2 70 
NS Emm_walk_happy_2 90 
13 Alx_knock_sad_1 40 
4 Alx_lift_sad_2 40 
9 Jua_throw_sad_2 90 
3 Jan_walk_sad_2 100 
NS Ale_knock_sad_2 40 
NS Ali_knock_sad_2 40 
NS Ali_lift_sad_1 30 
NS Ali_throw_sad_1 70 
NS Alx_walk_sad_2 80 
NS Jua_throw _sad_2 90 
*The stimuli name is comprised of the start of actors identifier, action type, emotion type and 
take number. 
 
TABLE L2. Final E-Motion Test of Full Figure, Line and Dot stimuli in Order 
Presented to Control and MND Participants in Main Study 
FIGURE 
1. Happy walk 
2. Afraid lift 
3. Sad walk 
4. Sad lift 
5. Happy lift 
6. Happy throw 
7. Angry throw 
8. Angry walk 
9. Sad throw 
10. Afraid throw 
11. Angry lift 
12. Happy knock 
13. Sad knock 
14. Afraid walk 
15. Angry knock 
16. Afraid knock 
LINE  
17. Afraid walk 
18. Happy throw 
19. Sad walk 
20. Angry lift 
21. Happy knock 
22. Sad knock 
23. Angry walk 
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24. Angry throw 
25. Afraid throw 
26. Angry knock 
27. Happy lift 
28. Sad lift 
29. Happy walk 
30. Afraid knock 
31. Afraid lift 
32. Sad throw 
DOT POINT LIGHT  
33. Happy walk 
34. Sad lift 
35. Happy lift 
36. Angry lift 
37. Happy throw 
38. Angry walk 
39. Sad throw 
40. Angry knock 
41. Sad walk 
42. Afraid throw 
43. Afraid lift 
44. Afraid knock 
45. Angry throw 
46. Afraid walk 
47. Happy knock 
48. Sad knock 
 
 
Table L3. Control Participants in Main Study (n=15) Performance on E-Motion 
 
 
 
 
 
Table L4. MND Participants in the Main Study (n=15) Performance on E-Motion 
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